Compounds and methods for reducing pln expression
Patent Information
- Application Number
- HK62026127128
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-05
- Filing Date
- 2026-08-06
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
This invention provides oligomeric compounds, methods, and pharmaceutical compositions for reducing the content or activity of PLN RNA in cells or animals, and in some cases, for reducing the content of phosphoproteins in cells or animals. These oligomeric compounds, methods, and pharmaceutical compositions can be used to treat cardiomyopathy, heart failure, or arrhythmias. Abstract
Claims
CLAIMS1. An oligomeric duplex comprising a first oligomeric compound and a second oligomeric compound, wherein:(1) the first oligomeric compound comprises a modified oligonucleotide consisting of 8 to 50 linked nucleosides, wherein the nucleobase sequence of the first modified oligonucleotide comprises at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 contiguous nucleobases of the nucleobase sequence of any one of SEQ ID NOs: 3-314, 627-782, 939-976, 1033- 1038, 1254-1255, or 1258-1287, wherein each of the nucleosides of the first modified oligonucleotide independently comprises a modified sugar moiety or sugar surrogate and wherein at least one modified nucleoside and less than 40% of the nucleosides of the first modified oligonucleotide comprises a fluorine; and(2) the second oligomeric compound comprises a second modified oligonucleotide consisting of 8 to 50 contiguous linked nucleosides comprising a region having a nucleobase sequence complementary to a region of the first modified oligonucleotide, wherein the nucleobase sequence of the second modified oligonucleotide comprises at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 contiguous nucleobases of the nucleobase sequence of any one of SEQ ID NOs: 315-626, 783- 938, 977-1016, 1027-1032, 1256-1257, or 1288-1290, wherein each of the nucleosides of the second modified oligonucleotide independently comprises a modified sugar moiety or sugar surrogate and wherein less than 40% of the nucleosides of the second modified oligonucleotide comprises a fluorine.
2. The oligomeric duplex of claim 1, wherein the first modified oligonucleotide is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% or 100% complementary to an equal length portion of a PLN nucleic acid, wherein the PLN nucleic acid has the nucleobase sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
3. The oligomeric duplex of claim 1 or claim 2, wherein each of the nucleosides of the first modified oligonucleotide independently comprises and each of the nucleosides of the second modified oligonucleotide independently comprises (i) a modified sugar moiety or sugar surrogate, or (ii) a sugar moiety independently selected from a 2’-F sugar moiety, a 2 ’-MOE sugar moiety, a 2’-OMe sugar moiety, a 2’-deoxy sugar moiety, and a 3’-fluoro-hexitol sugar moiety, or (iii) a modified sugar moiety.
4. The oligomeric duplex of any one of claims 1-3, wherein fewer than 35%, fewer than 30%, fewer than 25%, fewer than 20%, fewer than 15 %, fewer than 14%, fewer than 13%, fewer than 12%, fewer than 10%, fewer than 5%, or fewer than 1% of the nucleosides in the first modified oligonucleotide comprises a fluorine.
5. The oligomeric duplex of any one of claims 1-4, wherein no more than 1 nucleoside, no more than 2 nucleosides, no more than 3 nucleosides, or no more than 4 nucleosides in the first modified oligonucleotide comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine.
6. The oligomeric duplex of any one of claims 1-5, wherein no more than 1 nucleoside, no more than 2 nucleosides, or no more than 3 nucleosides within the sequence of the first modified oligonucleotide between and including the third and twenty -first nucleosides counting from the 5 ’ end of the modified oligonucleotide comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine.
7. The oligomeric duplex of any one of claims 1-6, wherein one or more nucleoside(s) of the first modified oligonucleotide comprising i) a modified sugar moiety comprising a fluorine or ii) a sugar surrogate comprising a fluorine is / are independently selected from: i. the second nucleoside counting from the 5’ end, ii.the fourteenth and sixteenth nucleosides counting from the 5’ end, or iii. the second, fourteenth and sixteenth nucleosides counting from the 5’ end; wherein each i) modified sugar moiety comprising a fluorine or ii) sugar surrogate comprising a fluorine is independently a 2’-fluoro sugar moiety or a 3 ’ -fluoro -hexitol sugar moiety.
8. The oligomeric duplex of any one of claims 1-7, wherein no more than one of the sugar moieties comprising a fluorine in the first modified oligonucleotide is a 3’-fluoro-hexitol sugar moiety.
9. The oligomeric duplex of any one of claims 1-8, wherein one or more nucleosides of the first modified oligonucleotide is a 2 ’-deoxynucleoside.
10. The oligomeric duplex of claim 9, wherein the one or more 2 ’-deoxynucleosides is one or more nucleosides in a region of the sequence of the first modified oligonucleotide between and including the fifth nucleoside to the sixteenth nucleoside counting from the 5 ’ end of the first modified oligonucleotide.
11. The oligomeric duplex of claim 10, wherein the one or more 2 ’-deoxynucleosides is in a region of the sequence of the first modified oligonucleotide that is any of the fifth, and / or sixth, and / or seventh nucleosides or that is any of the fourteenth, and / or fifteenth, and / or sixteenth nucleosides counting from the 5’ end of the first modified oligonucleotide.
12. The oligomeric duplex of any one of claims 9-11, wherein fewer than 20%, or fewer than 15%, of the nucleosides of the first modified oligonucleotide comprises a fluorine.
13. The oligomeric duplex of any one of claims 9-12, wherein the one or more 2’- deoxynucleosides is the fifth, and / or sixth, and / or seventh nucleoside(s) counting from the 5’ end of the first modified oligonucleotide.
14. The oligomeric duplex of any one of claims 9-13, wherein only one or only two nucleosides of the first modified oligonucleotide are 2’-deoxynucleosides.
15. The oligomeric duplex of claim 14, wherein the two 2 ’-deoxynucleosides are the fifth and seventh nucleosides, or the fourteenth and sixteenth nucleosides, counting from the 5 ’ end of the first modified oligonucleotide.
16. The oligomeric duplex of claim 14, wherein the only 2 ’-deoxynucleoside is the sixth or sixteenth nucleoside counting from the 5’ end of the first modified oligonucleotide.
17. The oligomeric duplex of any one of claims 1-8, wherein none of the nucleosides of the first modified oligonucleotide is a 2 ’-deoxynucleoside.
18. The oligomeric duplex of any one of claims 1-17, wherein the first oligomeric compound comprises a two -nucleoside overhang comprising the 3 ’-terminal nucleoside and the nucleoside immediately 5’ of the 3 ’-terminal nucleoside of the first modified oligonucleotide.
19. The oligomeric duplex of claim 18, wherein the overhang nucleosides are two modified adenosine (AA) nucleosides, two modified uridine (UU) nucleosides, two modified inosine (II) nucleosides, or two modified nucleosides wherein one is inosine and one is adenosine (Al or IA).
20. The oligomeric duplex of any one of claims 1-19, wherein one or more of the nucleosides of the first modified oligonucleotide independently comprises a sugar surrogate or a bicyclic sugar moiety.
21. The oligomeric duplex of claim 20, wherein the bicyclic sugar moiety comprises a 2’-4’ bridge selected from -O-CH2-; and -O-CH(CHs)-.
22. The oligomeric duplex of any one of claims 1-21, wherein one or more of the nucleosides of the first modified oligonucleotide comprises a 2’-OMe sugar moiety.
23. The oligomeric duplex of claim 22, wherein at least 10%, at least 20%, at least 30%, at least 40%, at least 50% or at least 60% of the nucleosides of the first modified oligonucleotide comprise a 2’-OMe sugar moiety.
24. The oligomeric duplex of claim 22 or claim 23, wherein the one or more nucleosides comprising a 2’-OMe sugar moiety are in a region of the sequence of the first modified oligonucleotide between and including the third and twenty -first nucleosides counting from the 5’ end of the first modified oligonucleotide, and / or wherein the first two nucleosides counting from the 5’ end of the first modified oligonucleotide and / or the first two nucleosides counting from the 3’ end of the first modified oligonucleotide are modified nucleosides independently comprising a sugar surrogate or a modified sugar moiety other than a 2’-OMe sugar moiety.
25. The oligomeric duplex of claim 22 or claim 23, wherein the 3’-terminal nucleoside of the first modified oligonucleotide comprises a 2’-OMe sugar moiety and / or the nucleoside immediately 5’ of the 3 ’-terminal nucleoside of the first modified oligonucleotide comprises a 2’-OMe sugar moiety.
26. The oligomeric duplex of any one of claims 1-25, wherein one or more of the nucleosides of the first modified oligonucleotide comprise a 2 ’-MOE sugar moiety.
27. The oligomeric duplex of claim 26, wherein the 5’- and / or 3 ’-terminal nucleosides of the first modified oligonucleotide comprise a 2’-MOE sugar moiety.
28. The oligomeric duplex of any one of claims 1-27, wherein the nucleoside immediately 5’ of the 3 ’-terminal nucleoside of the first modified oligonucleotide comprises a 2’-M0E sugar moiety.
29. The oligomeric duplex of any one of claims 1-24 and 26-28, wherein the 5’- and 3’-terminal nucleosides of the first modified oligonucleotide comprise a 2’-M0E sugar moiety and the nucleoside immediately 5’ of the 3’-terminal nucleoside of the first modified oligonucleotide comprises a 2’-M0E sugar moiety.
30. The oligomeric duplex of any one of claims 1-29, wherein the first oligomeric compound comprises a stabilized phosphate group attached to the 5 ’-terminal nucleoside of the first modified oligonucleotide.
31. The oligomeric duplex of claim 30, wherein the stabilized phosphate group comprises a cyclopropyl phosphonate or a vinyl phosphonate.
32. The oligomeric duplex of any one of claims 1-31, wherein the duplex comprises a conjugate group comprising a conjugate moiety and a conjugate linker.
33. The oligomeric duplex of claim 32, wherein the conjugate group comprises a cell -targeting moiety.
34. The oligomeric duplex of claim 32, wherein the conjugate moiety comprises an active drug substance, an aliphatic chain, a lipid, a peptide, a protein, a hydrocarbon, a polyamine, a polyamide, a polyether, a thioether, an aptamer, an antibody, an antibody fragment, a vitamin, a fatty acid, a carbohydrate, an intercalator, or a reporter molecule.
35. The oligomeric duplex of claim 32, wherein the conjugate group comprises a C22 alkyl, C20 alkyl, C17 alkyl, Cl 6 alkyl, CIO alkyl, C21 alkyl, C19 alkyl, Cl 8 alkyl, C15 alkyl, C14 alkyl, C13 alkyl, C12 alkyl, Cl l alkyl, C9 alkyl, C8 alkyl, C7 alkyl, C6 alkyl, or C5 alkyl, wherein the alkyl chain optionally has one or more unsaturated bonds.
36. The oligomeric duplex of claim 32, wherein the conjugate group comprises a 6- palmitamidohexyl moiety or a 2-(hydroxymethyl)-6-palmitamidohexyl moiety.
37. The oligomeric duplex of claim 32, wherein the conjugate group comprises a conjugate moiety that binds type 1 transferrin receptor (TfRl).
38. The oligomeric duplex of claim 37, wherein the conjugate moiety is selected from an antibody or fragment thereof, a protein or peptide, and an aptamer capable of binding TfRl .
39. The oligomeric duplex of claim 38, wherein the conjugate moiety is a cyclic protein or cyclic peptide.
40. The oligomeric duplex of claim 37, wherein the conjugate group comprises a bicycle ligand and a conjugate linker.
41. The oligomeric duplex of claim 40, wherein the bicycle ligand comprises a peptide consisting of 13-22 linked amino acids or amino acid mimetics and a molecular scaffold, wherein each of a first, asecond, and a third amino acid of the peptide comprises a reactive group, each of which separately forms a bond with the molecular scaffold, thereby forming two peptide loops attached to the molecular scaffold.
42. The oligomeric duplex of claim 41, wherein the peptide has an amino acid sequence selected from any one of SEQ ID NOs: 1062-1253 and wherein each cysteine forms a covalent bond with the molecular scaffold 1,T,1"-(1, 3, 5-triazinane-l, 3, 5-triyl)tris(2 -bromoethanone) (TATB) or the molecular scaffold l,r,l"-(l,3,5-triazinane-l,3,5-triyl)triprop-2-en-l-one (TATA).
43. The oligomeric duplex of claim 41, wherein the bicycle ligand or conjugate group has the structure:or a salt thereof, wherein Q is N3(BCY17901, SEQ ID NO: 1045), NH2(BCY21757, SEQ ID NO: 1202), SH (BCY21758, SEQ ID NO: 1203), a conjugate linker, or a conjugate linker covalently connected to an oligonucleotide.
44. The oligomeric duplex of any one of claims 32-43, wherein the conjugate group is conjugated to the second modified oligonucleotide.
45. The oligomeric duplex of any one of claims 32-43, wherein the conjugate group is attached to the 5’ end or 3’ end of the second modified oligonucleotide.
46. The oligomeric duplex of any one of claims 32-43, wherein the conjugate group is attached to the 5 ’-terminal nucleoside or the 3 ’-terminal nucleoside of the second modified oligonucleotide.
47. The oligomeric duplex of any one of claims 32-43, wherein the conjugate group is attached to the 5 ’-terminal nucleoside of the second modified oligonucleotide.
48. The oligomeric duplex of any one of claims 32-43, wherein the conjugate group is attached to the 3 ’-terminal nucleoside of the second modified oligonucleotide.
49. The oligomeric duplex of any one of claims 32-48, wherein the conjugate linker of the conjugate group consists of a single bond.
50. The oligomeric duplex of any one of claims 32-48, wherein the conjugate linker of the conjugate group is cleavable.
51. The oligomeric duplex of any one of claims 32-50, wherein the conjugate linker comprises 1 to 3 linker-nucleosides.
52. The oligomeric duplex of any one of claims 32-48, wherein the conjugate linker comprises a (bicyclo[6.1.0]nonyne)-formyl (BCN) moiety.
53. The oligomeric duplex of any one of claims 32-48, wherein the conjugate linker comprises a 6-(BCN-carbamate)-2-(hydroxymethyl)hexyl phosphoryl moiety or a 6-(BCN-carbamate)hexyl phosphoryl moiety.
54. The oligomeric duplex of claim 41, wherein the conjugate group has the structure:
55. The oligomeric duplex of claim 41, wherein the conjugate group has the structure:
56. The oligomeric duplex of any one of claims 1-55, wherein, the nucleobase sequence of the first modified oligonucleotide is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% or 100% complementary to an equal length portion within nucleobases selected from any one of 295-316, 296- 317, 297-318, 298-320, 299-320, 300-321, 301-322, 302-324, 303-324, 304-325, 304-326, 305-327, 306-325, 306-328, 307-328, 308-329, 309-330, 310-331, 311-332, 312-333, 313-334, 314-335, 315-336, 316-337, 317- 339, 318-339, 319-340, 320-341, 321-342, 322-344, 323-345, 324-345, 324-346, 325-345, 325-347, 326-347, 327-348, 328-349, 329-350, 330-351, 331-352, 332-353, 333-354, 334-355, 505-526, 506-528, 507-529, 508- 530, 509-531, 510-531, 511-532, 512-533, 513-535, 514-535, 514-536, 515-536, 516-535, 516-537, 517-538, 518-539, 519-541, 520-541, 521-542, 522-544, 523-544, 524-546, 535-556, 536-557, 537-558, 538-559, 539- 560, 540-561, 541-563, 542-563, 543-564, 544-565, 545-566, 546-567, 547-568, 548-570, 549-571, 550-572, 551-572, 552-574, 553-574, 554-575, 555-577, 556-578, 557-579, 558-580, 559-580, 560-581, 561-582, 562- 583, 563-584, 595-616, 596-618, 597-618, 598-620, 599-621, 600-622, 601-623, 602-623, 603-624, 604-625, 605-627, 606-628, 607-628, 608-629, 609-630, 610-631, 611-632, 612-633, 613-635, 665-687, 666-687, 667- 689, 668-689, 669-690, 670-691, 671-692, 672-694, 673-694, 674-695, 675-696, 676-697, 677-698, 678-700, 679-701, 680-702, 681-703, 682-703, 683-704, 684-705, 685-706, 686-708, 687-708, 688-709, 689-710, 690- 711, 691-712, 692-714, 693-715, 1675-1696, 1676-1698, 1677-1698, 1678-1699, 1679-1700, 1680-1702, 1681-1702, 1682-1703, 1683-1705, 1684-1705, 1685-1706, 1686-1707, 1687-1709, 1688-1709, 1689-1710, 1690-1712, 1691-1713, 1692-1714, or 1693-1714 of SEQ ID NO: 1.
57. The oligomeric duplex of any one of claims 1-55, wherein the nucleobase sequence of the first modified oligonucleotide is at least 80%, at least 85%, at least 90%, at least 95%, or 100% complementary to an equal length portion within the sequence of nucleobases 304-326, 306-325, 324-346, 325-345, 514-536, or 516-535 of SEQ ID NO: 1.
58. The oligomeric duplex of any one of claims 1-55, wherein the nucleobase sequence of the first modified oligonucleotide comprises at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 contiguous nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 3- 314, 627-782, 939-976, 1033-1038, 1254-1255, or 1258-1287.
59. The oligomeric duplex of any one of claims 1-55, wherein the nucleobase sequence of the first modified oligonucleotide comprises the nucleobase sequence of any one of SEQ ID NOs: 3-314, 627- 782, 939-976, 1033-1038, 1254-1255 or 1258-1287.
60. The oligomeric duplex of any one of claims 1-55, wherein the nucleobase sequence of the first modified oligonucleotide consists of the nucleobase sequence of any one of SEQ ID NOs: 3-314, 627- 782, 939-976, 1033-1038, 1254-1255 or 1258-1287.
61. The oligomeric duplex of any one of claims 1-55, wherein the nucleobase sequence of the first modified oligonucleotide comprises at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 contiguous nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 29, 171, 176, 967, 968, 971, 972, 974, 975, 1254, 1255, 1033-1038, 1254-1255, or 1258-1287.
62. The oligomeric duplex of any one of claims 1-55, wherein the nucleobase sequence of the first modified oligonucleotide comprises the nucleobase sequence of any one of SEQ ID NOs: 29, 171, 176, 967, 968, 971, 972, 974, 975, 1254, 1255, or 1033-1038, 1254-1255, or 1258-1287.
63. The oligomeric duplex of any one of claims 1-55, wherein the nucleobase sequence of the first modified oligonucleotide consists of the nucleobase sequence of any one of SEQ ID NOs: 29, 171, 176, 967, 968, 971, 972, 974, 975, 1254, 1255, 1033-1038, 1254-1255, or 1258-1287.
64. The oligomeric duplex of any one of claims 1-63, wherein the first modified oligonucleotide and the second modified oligonucleotide each independently consist of 18 to 30, 18 to 25, 18 to 24, 18 to 23, 18 to 22, 18 to 21, 18 to 19, 19 to 30, 19 to 25, 19 to 24, 19 to 23, 19 to 21, 19 to 20, 20 to 30, 20 to 25, 20 to 24, 20 to 23, 20 to 22, 20 to 21, 21 and 19, 21 and 20, 23 and 21, 23 and 22, or 22 and 21 linked nucleosides.
65. The oligomeric duplex of any one of claims 1-64, wherein the first modified oligonucleotide consists of 23, 22, or 21 nucleosides.
66. The oligomeric duplex of any one of claims 1-65, wherein the second modified oligonucleotide consists of 21 nucleosides.
67. The oligomeric duplex of any one of claims 1-65, wherein the first modified oligonucleotide consists of 23 nucleosides and the second modified oligonucleotide consists of 21 nucleosides.
68. The oligomeric duplex of any one of claims 1-65, wherein the first modified oligonucleotide consists of 22 nucleosides and the second modified oligonucleotide consists of 21 nucleosides.
69. The oligomeric duplex of any one of claims 1-65, wherein the first modified oligonucleotide consists of 21 nucleosides and the second modified oligonucleotide consists of 21 nucleosides.
70. The oligomeric duplex of any one of claims 1-69, wherein the first modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: efyyydyyyyyyyfyfyyyyyee, efyyydyyyyyyyfyfyyyyyyy, e[FHNA]yyydyyyyyyyfyfyyyyyee, e[FHNA]yyydyyyyyyyfyfyyyyyyy, efyydydyyyyyyfyfyyyyyee, efyydydyyyyyyfyfyyyyyyy, e [FHNA]yydydyyyyyyfyfyyyyyee, e [FHNA]yydydyyyyyyfyfyyyyyyy , efyyyfyyyyyyyfyfyyyyyyy, efyyyfyyyyyyyfyfyyyyyey, efyyyyyyyyyyyfyfyyyyyee, efyyyfyyyyyyyfyfyyyyyee, efyyyyyyyyyyyfyyyyyyyee, efyyyyyyyyyyyfyyyyyyyyy, e[FHNA]yyyfyyyyyyyfyfyyyyyee, e[FHNA]yyyfyyyyyyyfyfyyyyyyy, efyyydyyyyyyydydyyyyyee, efyyydyyyyyyydydyyyyyyy, efyydydyyyyyyfyfyyyyyyy, efyyyfyyyyyyyfyyyyyyyee, efyyyfyyyyyyyfyyyyyyyyy, efyyyyyyyyyyyfyfyyyyyee, efyyyyyyyyyyyfyfyyyyyyy, e[FHNA]yydydyyyyfyfyfyyyyyyy, efyyyfyyyyyyyfydyyyyyyy, efyyyfyyyyyyyfydyyyyyee, efyydydyyyyyyfyfyyyyye, efyydydyyyyyyfyfyyyyyy, efyyydyyyyyyyfyfyyyyye, efyyydyyyyyyyfyfyyyyyy, efyyyyyyyyyyyfyfyyyyye, efyyyyyyyyyyyfyfyyyyyy, efyydydyyyyyyfyfyyyyy, efyyydyyyyyyyfyfyyyyy, efyyyyyyyyyyyfyfyyyyy, efyyyfyyyyyyyfyfyyyee, and efyyyfyyyyyyyfyfyyyyy, wherein each “d” represents a 2’-deoxy sugar moiety, each “y” represents a 2’-0Me sugar moiety, each “e” represents a 2’-M0E sugar moiety, each “f” represents a 2’-fluoro sugar moiety, and each “[FHNA]” represents a 3’-fluoro-hexitol sugar moiety.
71. The oligomeric duplex of any one of claims 1-69, wherein the first modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: efyydydyyyyyyfyfyyyyyee, efyyydyyyyyyyfyfyyyyyee, efyydydyyyyyyfyfyyyyyyy, e[FHNA]yydydyyyyfyfyfyyyyyyy, efyyyyyyyyyyyfyfyyyyyee, efyyydyyyyyyyfyfyyyyyyy, efyydydyyyyyyfyfyyyyye, efyydydyyyyyyfyfyyyyyy, efyyydyyyyyyyfyfyyyyye, efyyydyyyyyyyfyfyyyyyy, efyyyyyyyyyyyfyfyyyyye, efyyyyyyyyyyyfyfyyyyyy, efyydydyyyyyyfyfyyyyy, efyyydyyyyyyyfyfyyyyy, and efyyyyyyyyyyyfyfyyyyy.
72. The oligomeric duplex of any one of claims 1-71, wherein the first modified oligonucleotide comprises at least one modified intemucleoside linkage.
73. The oligomeric duplex of claim 72, wherein at least one modified intemucleoside linkage is a phosphorothioate or mesyl phosphoramidate intemucleoside linkage.
74. The oligomeric duplex of claim 72, wherein fewer than 50%, fewer than 40%, fewer than 30%, fewer than 20%, or fewer than 10% of the intemucleoside linkages of the first modified oligonucleotide are modified intemucleoside linkages.
75. The oligomeric duplex of any one of claims 1-74, wherein each intemucleoside linkage of the first modified oligonucleotide is independently selected from a phosphodiester intemucleoside linkage and a phosphorothioate intemucleoside linkage.
76. The oligomeric duplex of claim 75, wherein the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 5 ’ end of the first modified oligonucleotide are modified intemucleoside linkages.
77. The oligomeric duplex of claim 75, wherein the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 3 ’ end of the first modified oligonucleotide are modified intemucleoside linkages.
78. The oligomeric duplex of claim 75, wherein the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 5 ’ end of the first modified oligonucleotide, and the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 3’ end of the first modified oligonucleotide are modified intemucleoside linkages.
79. The oligomeric duplex of any one of claims 72-78, wherein the modified intemucleoside linkages are phosphorothioate intemucleoside linkages.
80. The oligomeric duplex of claim 78 or claim 79, wherein all other intemucleoside linkages in the first modified oligonucleotide are phosphodiester intemucleoside linkages.
81. The oligomeric duplex of claim 80, wherein the first modified oligonucleotide has an intemucleoside linkage motif of ssooooooooooooooooooss and a sugar motif (5’ to 3’) selected from among: efyydydyyyyyyfyfyyyyyee, efyyydyyyyyyyfyfyyyyyee, efyydydyyyyyyfyfyyyyyyy, e[FHNA]yydydyyyyfyfyfyyyyyyy, efyyyyyyyyyyyfyfyyyyyee and efyyydyyyyyyyfyfyyyyyyy; wherein each “d” represents a 2’-deoxy sugar moiety, each “y” represents a 2’-OMe sugar moiety, each “e” represents a 2’-MOE sugar moiety, each “f” represents a 2’-fluoro sugar moiety, each “[FHNA]” represents a 3’-fluoro- hexitol sugar moiety, each “o” represents a phosphodiester intemucleoside linkage and each “s” represents a phosphorothioate intemucleoside linkage.
82. The oligomeric duplex of claim 72, wherein: 1) the first modified oligonucleotide has an intemucleoside linkage motif of ssoooooooooooooooooos and a sugar motif (5’ to 3’) selected from among: efyydydyyyyyyfyfyyyyye, efyydydyyyyyyfyfyyyyyy, efyyydyyyyyyyfyfyyyyye, efyyydyyyyyyyfyfyyyyyy, efyyyyyyyyyyyfyfyyyyye, and efyyyyyyyyyyyfyfyyyyyy; or 2) the first modified oligonucleotide has an intemucleoside linkage motif of ssoooooooooooooooooo and a sugar motif (5’ to 3’) selected from among: efyydydyyyyyyfyfyyyyy, efyyydyyyyyyyfyfyyyyy, and efyyyyyyyyyyyfyfyyyyy; wherein each “d” represents a 2’-deoxy sugar moiety, each “y” represents a 2’-OMe sugar moiety, each “e” represents a 2’-MOE sugar moiety, each “f” represents a 2’-fluoro sugar moiety, each “o” represents a phosphodiester intemucleoside linkage and each “s” represents a phosphorothioate intemucleoside linkage.
83. The oligomeric duplex of any one of claims 1-82, wherein fewer than 30%, fewer than 25%, fewer than 20%, fewer than 15 %, fewer than 14%, fewer than 13%, fewer than 12%, fewer than 10%, or fewer than 5% of the nucleosides in the second modified oligonucleotide comprise a fluorine.
84. The oligomeric duplex of any one of claims 1-82, wherein no more than 4 nucleosides, no more than 3 nucleosides, no more than 2 nucleosides, or no more than 1 nucleoside in the second modified oligonucleotide comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine; and wherein optionally none of the nucleosides before the seventh or after the eleventh nucleoside counting from the 5 ’ end of the second modified oligonucleotide comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine.
85. The oligomeric duplex of any one of claims 1-84, wherein one or more of the seventh, ninth and eleventh nucleosides counting from the 5 ’ end of the second modified oligonucleotide comprises a modified sugar moiety comprising a fluorine.
86. The oligomeric duplex of claim 85, wherein two or more of the seventh, ninth and eleventh nucleosides counting from the 5 ’ end of the second modified oligonucleotide comprise a modified sugar moiety comprising a fluorine.
87. The oligomeric duplex of claim 85, wherein the seventh, ninth and eleventh nucleosides counting from the 5 ’ end of the second modified oligonucleotide comprise a modified sugar moiety comprising a fluorine.
88. The oligomeric duplex of any one of claims 1-84, wherein one or both of the tenth and eleventh nucleosides counting from the 5 ’ end of the second modified oligonucleotide comprises a modified sugar moiety comprising a fluorine.
89. The oligomeric duplex of any one of claims 84-88, wherein the modified sugar moiety comprising a fluorine is a 2 ’-fluoro sugar moiety.
90. The oligomeric duplex of any one of claims 1-89, wherein fewer than 30%, fewer than 25%, fewer than 20%, fewer than 15 %, fewer than 14%, fewer than 13%, fewer than 12%, fewer than 10%, fewer than 5%, or fewer than 1% of the total nucleosides in the oligomeric duplex comprise a fluorine.
91. The oligomeric duplex of any one of claims 1-90, wherein one or more of the nucleosides of the second modified oligonucleotide independently comprises a sugar surrogate or a bicyclic sugar moiety.
92. The oligomeric duplex of claim 91, wherein the bicyclic sugar moiety comprises a 2’-4’ bridge selected from -O-CH2-; and -O-CH(CH3)-.
93. The oligomeric duplex of any one of claims 1-92, wherein one or more of the nucleosides of the second modified oligonucleotide comprises a 2’-OMe sugar moiety.
94. The oligomeric duplex of claim 93, wherein at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 65%, at least 70%, at least 80%, at least 85%, or at least 90% of the nucleosides of the second modified oligonucleotide comprise a 2’-OMe sugar moiety.
95. The oligomeric duplex of claim 93 or claim 94, wherein the one or more nucleosides comprising a 2’-OMe sugar moiety are in a region of the sequence of the second modified oligonucleotide between and including the third and nineteenth nucleosides counting from the 5 ’ end of the second modified oligonucleotide.
96. The oligomeric duplex of claim 93 or claim 94, wherein the 3 ’-terminal nucleoside of the second modified oligonucleotide comprises a 2’-OMe sugar moiety and / or the nucleoside immediately 5’ of the 3’-terminal nucleoside of the second modified oligonucleotide comprises a 2’-OMe sugar moiety.
97. The oligomeric duplex of any one of claims 93, 94, and 96, wherein the 5 ’-terminal nucleoside of the second modified oligonucleotide comprises a 2’-OMe sugar moiety and / or the nucleoside immediately 3’ of the 5’-terminal nucleoside of the second modified oligonucleotide comprises a 2’-OMe sugar moiety.
98. The oligomeric duplex of claim 93 or claim 94, wherein the 5 ’-terminal nucleoside, the nucleoside immediately 3’ of the 5 ’-terminal nucleoside, the 3 ’-terminal nucleoside, and the nucleoside immediately 5’ of the 3’-terminal nucleoside of the second modified oligonucleotide comprises a 2’-OMe sugar moiety.
99. The oligomeric duplex of any one of claims 1-98, wherein one or more of the nucleosides of the second modified oligonucleotide comprise a 2 ’-MOE sugar moiety.
100. The oligomeric duplex of any one of claims 1-95, wherein the 3’-terminal nucleoside of the second modified oligonucleotide comprises a 2’-MOE sugar moiety and / or the nucleoside immediately 5’ of the 3 ’-terminal nucleoside of the second modified oligonucleotide comprises a 2’-MOE sugar moiety.
101. The oligomeric duplex of any one of claims 1-96, 99 and 100, wherein the 5’-terminal nucleoside of the second modified oligonucleotide comprises a 2’-MOE sugar moiety and / or the nucleoside immediately 3’ of the 5 ’-terminal nucleoside of the second modified oligonucleotide comprises a 2’-MOE sugar moiety.
102. The oligomeric duplex of any one of claims 1-95, wherein the 5’-terminal nucleoside, the nucleoside immediately 3’ of the 5 ’-terminal nucleoside, the 3 ’-terminal nucleoside, and the nucleoside immediately 5’ of the 3 ’-terminal nucleoside of the second modified oligonucleotide comprises a 2’-MOE sugar moiety.
103. The oligomeric duplex of any one of claims 1-102, wherein the second modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: eeyyyyfyfyfyyyyyyyyee, eeyyyyfyfyfyyyyyyyyyy, yyyyyyfyfyfyyyyyyyyee, yyyyyyfyfyfyyyyyyyyyy, eeyyyyfyfffyyyyyyyyee, eeyyyyfyfffyyyyyyyyyy, yyyyyyfyfffyyyyyyyyee, yyyyyyfyfffyyyyyyyyyy, eeyyyyyyyffyyyyyyyyee, eeyyyyyyyffyyyyyyyyyy, yyyyyyyyyffyyyyyyyyee, yyyyyyyyyffyyyyyyyyyy, eeyyyyyffyyyyyyyyee, eeyyyyyffyyyyyyyyyy, yyyyyyyffyyyyyyyyee, yyyyyyyffyyyyyyyyyy, yyyyyyfyfffyyyyyyyy, eeyyyyfyfffyyyyyyee, eeyyyyfyfffyyyyyyyy, yyyyyyfyfffyyyyyyee, eeyyfyfffyyyyyyyyee, eeyyfyfffyyyyyyyyyy, yyyyfyfffyyyyyyyyee, yyyyfyfffyyyyyyyyyy, eeyyyyyyyydyyyyyyyyee, eeyyyyyyyydyyyyyyyyyy, yyyyyyyyyydyyyyyyyyee, yyyyyyyyyydyyyyyyyyyy, eeyyyyyyyyyyyyyyyyyee, eeyyyyyyyyyyyyyyyyyyy, yyyyyyyyyyyyyyyyyyyee, and yyyyyyyyyyyyyyyyyyyyy wherein each “y” represents a 2’-OMe sugar moiety, each “e” represents a 2’-MOE sugar moiety, each “f ’ represents a 2’- fluoro sugar moiety, and each “d” represents a 2’-deoxy sugar moiety.
104. The oligomeric duplex of any one of claims 1-102, wherein the second modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: eeyyyyyyyffyyyyyyyyee, eeyyyyfyfyfyyyyyyyyee, yyyyyyyyyffyyyyyyyyyy, and yyyyyyfyfyfyyyyyyyyyy, wherein each “y” represents a 2’-OMe sugar moiety, each “e” represents a 2’-MOE sugar moiety, and each “f ’ represents a 2’- fluoro sugar moiety.
105. The oligomeric duplex of any one of claims 1-104, wherein (1) the nucleobase of the 3’- terminal nucleoside and / or of the nucleoside immediately 5’ of the 3 ’-terminal nucleoside of the first modified oligonucleotide and / or of the second modified oligonucleotide is an adenine or thymine; and / or (2) the nucleobase of the 5 ’-terminal nucleoside of the first modified oligonucleotide is a thymine.
106. The oligomeric duplex of any one of claims 1-104, wherein the nucleobase of the 3’-terminal nucleoside and the nucleoside immediately 5’ of the 3 ’-terminal nucleoside of the first modified oligonucleotide is an adenine, and the nucleobase of the 5 ’-terminal nucleoside of the first modified oligonucleotide is a thymine; and wherein the nucleobase of the 3 ’-terminal nucleoside of the second modified oligonucleotide is an adenine and the nucleobase of the nucleoside immediately 5’ of the 3’- terminal nucleoside of the second modified oligonucleotide is a thymine or uracil.
107. The oligomeric duplex of any one of claims 1-106, wherein the second modified oligonucleotide comprises at least one modified intemucleoside linkage.
108. The oligomeric duplex of claim 107, wherein at least one modified intemucleoside linkage is a phosphorothioate or mesyl phosphoramidate intemucleoside linkage.
109. The oligomeric duplex of claim 107, wherein fewer than 50%, fewer than 40%, fewer than 30%, fewer than 20%, or fewer than 10% of the intemucleoside linkages of the second modified oligonucleotide are modified intemucleoside linkages.
110. The oligomeric duplex of any one of claims 107-109, wherein each intemucleoside linkage of the second modified oligonucleotide is independently selected from a phosphodiester intemucleoside linkage and a phosphorothioate intemucleoside linkage.
111. The oligomeric duplex of any one of claims 107-109, wherein the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 5 ’ end of the second modified oligonucleotide are modified intemucleoside linkages.
112. The oligomeric duplex of any one of claims 107-109 and 111, wherein the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 3 ’ end of the second modified oligonucleotide are modified intemucleoside linkages.
113. The oligomeric duplex of any one of claims 107-109, wherein the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 5 ’ end of the second modified oligonucleotide, and the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 3 ’ end of the second modified oligonucleotide are modified intemucleoside linkages.
114. The oligomeric duplex of any one of claims 107-113, wherein the modified intemucleoside linkages are phosphorothioate intemucleoside linkages.
115. The oligomeric duplex of claim 114, wherein all other intemucleoside linkages in the second modified oligonucleotide are phosphodiester intemucleoside linkages.
116. The oligomeric duplex of claim 115, wherein the second modified oligonucleotide has an intemucleoside linkage motif of ssooooooooooooooooss and a sugar motif (5’ to 3’) selected from among: eeyyyyyyyffyyyyyyyyee, eeyyyyfyfyfyyyyyyyyee, yyyyyyyyyffyyyyyyyyyy, and yyyyyyfyfyfyyyyyyyyyy; wherein each “ “y” represents a 2’-OMe sugar moiety, each “e” represents a 2 ’-MOE sugar moiety, each “f ’ represents a 2 ’-fluoro sugar moiety, each “o” represents a phosphodiester intemucleoside linkage and each “s” represents a phosphorothioate intemucleoside linkage.
117. The oligomeric duplex of any one of claims 1-116, wherein the nucleobase sequence of the second modified oligonucleotide comprises at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 contiguous nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 315-626, 783-938, 977-1016, 1027-1032, 1256-1257, or 1288-1290.
118. The oligomeric duplex of any one of claims 1-116, wherein the nucleobase sequence of the second modified oligonucleotide comprises the nucleobase sequence of any one of SEQ ID NOs: 315-626, 783-938, 977-1016, 1027-1032, 1256-1257, or 1288-1290.
119. The oligomeric duplex of any one of claims 1-116, wherein the nucleobase sequence of the second modified oligonucleotide consists of the nucleobase sequence of any one of SEQ ID NOs: 315-626, 783-938, 977-1016, 1027-1032, 1256-1257, or 1288-1290.
120. The oligomeric duplex of any one of claims 1-116, wherein the nucleobase sequence of the second modified oligonucleotide comprises at least 16 contiguous nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 341, 483, 488, 1011-1016, 1027-1032, 1256-1257, or 1288-1290.
121. The oligomeric duplex of any one of claims 1-116, wherein the nucleobase sequence of the second modified oligonucleotide comprises the nucleobase sequence of any one of SEQ ID NOs: 341, 483, 488, 1011-1016, 1027-1032, 1256-1257, or 1288-1290.
122. The oligomeric duplex of any one of claims 1-116, wherein the nucleobase sequence of the second modified oligonucleotide consists of the nucleobase sequence of any one of SEQ ID NOs: 341, 483, 488, 1011-1016, 1027-1032, 1256-1257, or 1288-1290.
123. An oligomeric duplex comprising:(1) a first oligomeric compound comprising a first modified oligonucleotide consisting of 18 to 30 contiguous linked nucleosides that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% complementary, or 100% complementary to an equal length portion within nucleobases selected from any one of 295-316, 296-317, 297-318, 298-320, 299-320, 300-321, 301-322, 302-324, 303-324, 304-325, 304-326, 305-327, 306-325, 306-328, 307-328, 308-329, 309-330, 310-331, 311- 332, 312-333, 313-334, 314-335, 315-336, 316-337, 317-339, 318-339, 319-340, 320-341, 321-342, 322-344, 323-345, 324-345, 324-346, 325-345, 325-347, 326-347, 327-348, 328-345, 328-349, 329- 350, 330-351, 331-352, 332-353, 333-354, 334-355, 505-526, 506-528, 507-529, 508-530, 509-531, 510-531, 511-532, 512-533, 513-535, 514-535, 514-536, 515-536, 516-535, 516-537, 517-538, 518- 539, 519-541, 520-541, 521-542, 522-544, 523-544, 524-546, 535-556, 536-557, 537-558, 538-559, 539-560, 540-561, 541-563, 542-563, 543-564, 544-565, 545-566, 546-567, 547-568, 548-570, 549- 571, 550-572, 551-572, 552-574, 553-574, 554-575, 555-577, 556-578, 557-579, 558-580, 559-580, 560-581, 561-582, 562-583, 563-584, 595-616, 596-618, 597-618, 598-620, 599-621, 600-622, 601- 623, 602-623, 603-624, 604-625, 605-627, 606-628, 607-628, 608-629, 609-630, 610-631, 611-632, 612-633, 613-635, 665-687, 666-687, 667-689, 668-689, 669-690, 670-691, 671-692, 672-694, 673- 694, 674-695, 675-696, 676-697, 677-698, 678-700, 679-701, 680-702, 681-703, 682-703, 683-704, 684-705, 685-706, 686-708, 687-708, 688-709, 689-710, 690-711, 691-712, 692-714, 693-715, 1675- 1696, 1676-1698, 1677-1698, 1678-1699, 1679-1700, 1680-1702, 1681-1702, 1682-1703, 1683- 1705, 1684-1705, 1685-1706, 1686-1707, 1687-1709, 1688-1709, 1689-1710, 1690-1712, 1691- 1713, 1692-1714, or 1693-1714 of SEQ ID NO: 1, and(2) a second oligomeric compound comprising a second modified oligonucleotide consisting of 16 to 28 contiguous linked nucleosides that is at least 90% complementary to an equal length portion of the first modified oligonucleotide;wherein:(a) each of the nucleosides of the first modified oligonucleotide and each of the nucleosides of the second modified oligonucleotide comprise a modified sugar moiety or a sugar surrogate,(b) at least one of the modified sugar moiety or sugar surrogate of the first modified oligonucleotide comprises a fluorine, and(c) fewer than 40% of the nucleosides of the first modified oligonucleotide comprise a fluorine.
124. An oligomeric duplex comprising, (1) a first oligomeric compound comprising a first modified oligonucleotide consisting of 18 to 30 contiguous linked nucleosides, wherein the nucleobase sequence of the first modified oligonucleotide comprises at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 contiguous nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 3- 314, 627-782, 939-976, 1033-1038, 1254-1255, or 1258-1287; and (2) a second oligomeric compound comprising a second modified oligonucleotide consisting of 16 to 28 contiguous linked nucleosides that is at least 90% complementary to an equal length portion of the first modified oligonucleotide; wherein: (a) each of the nucleosides of the first modified oligonucleotide and each of the nucleosides of the second modified oligonucleotide comprise a modified sugar moiety or a sugar surrogate, (b) at least one of the modified sugar moiety or sugar surrogate of the first modified oligonucleotide comprises a fluorine, and (c) fewer than 40% of the nucleosides of the first modified oligonucleotide comprise a fluorine.
125. The oligomeric duplex of claim 124, wherein each nucleoside of the oligomeric duplex comprises (i) a modified sugar moiety or (ii) a sugar moiety independently selected from a 2’-F sugar moiety, a 2’-MOE sugar moiety, a 2’-OMe sugar moiety, a 2’-deoxy sugar moiety, and a 3’-fluoro-hexitol sugar moiety.
126. The oligomeric duplex of claim 124, wherein the nucleobase sequence of the first modified oligonucleotide comprises or consists of the nucleobase sequence of any one of SEQ ID NOs: 3-314, 627- 782, 939-976, 1033-1038, 1254-1255, or 1258-1287.
127. The oligomeric duplex of claim 124, wherein the nucleobase sequence of the first modified oligonucleotide comprises at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 contiguous nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 29, 171, 176, 967, 968, 971, 972, 974, 975, 1033-1038, 1254-1255, or 1258-1287.
128. The oligomeric duplex of claim 124, wherein the nucleobase sequence of the first modified oligonucleotide comprises the nucleobase sequence of any one of SEQ ID NOs: 29, 171, 176, 967, 968, 971, 972, 974, 975, 1033-1038, 1254-1255, or 1258-1287.
129. The oligomeric duplex of claim 124, wherein the nucleobase sequence of the first modified oligonucleotide consists of the nucleobase sequence of any one of SEQ ID NOs: 29, 171, 176, 967, 968, 971, 972, 974, 975, 1033-1038, 1254-1255, or 1258-1287.
130. The oligomeric duplex of claim 124, wherein the nucleobase sequence of the second modified oligonucleotide comprises least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 contiguous nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 315-626, 783-938, 977-1016, 1027-1032, 1256- 1257, or 1288-1290.
131. The oligomeric duplex of claim 126, wherein the nucleobase sequence of the second modified oligonucleotide comprises the nucleobase sequence of any one of SEQ ID NOs: 315-626, 783-938, 977-1016, 1027-1032, 1256-1257, or 1288-1290.
132. The oligomeric duplex of claim 126, wherein the nucleobase sequence of the second modified oligonucleotide consists of the nucleobase sequence of any one of SEQ ID NOs: 315-626, 783-938, 977-1016, 1027-1032, 1256-1257, or 1288-1290.
133. The oligomeric duplex of claim 127, wherein the nucleobase sequence of the second modified oligonucleotide comprises at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 contiguous nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 341, 483, 488, 1011-1016, 1027-1032, 1256-1257, or 1288-1290.
134. The oligomeric duplex of claim 128, wherein the nucleobase sequence of the second modified oligonucleotide comprises the nucleobase sequence of any one of SEQ ID NOs: 341, 483, 488, 1011-1016, 1027-1032, 1256-1257, or 1288-1290.
135. The oligomeric duplex of claim 129, wherein the nucleobase sequence of the second modified oligonucleotide consists of the nucleobase sequence of any one of SEQ ID NOs: 341, 483, 488, 1011-1016, 1027-1032, 1256-1257, or 1288-1290.
136. The oligomeric duplex of any one of claims 123-135, wherein (1) the nucleobase of the 3’- terminal nucleoside and / or of the nucleoside immediately 5’ of the 3 ’-terminal nucleoside of the first modified oligonucleotide and / or of the second modified oligonucleotide is an adenine or thymine; and / or (2) the nucleobase of the 5 ’-terminal nucleoside of the first modified oligonucleotide is a thymine.
137. The oligomeric duplex of any one of claims 123-135, wherein the nucleobase of the 3’- terminal nucleoside and the nucleoside immediately 5’ of the 3 ’-terminal nucleoside of the first modified oligonucleotide is an adenine, and the nucleobase of the 5 ’-terminal nucleoside of the first modified oligonucleotide is a thymine; and wherein the nucleobase of the 3 ’-terminal nucleoside of the second modified oligonucleotide is an adenine and the nucleobase of the nucleoside immediately 5’ of the 3’- terminal nucleoside of the second modified oligonucleotide is a thymine or uracil.
138. The oligomeric duplex of any one of claims 123-135, wherein the first oligomeric compound comprises a two -nucleoside overhang comprising the 3 ’-terminal nucleoside and the nucleoside immediately 5’ of the 3 ’-terminal nucleoside of the first modified oligonucleotide.
139. The oligomeric duplex of claim 138, wherein the overhang nucleosides are two modified adenosine (AA) nucleosides, two modified uridine (UU) nucleosides, two modified inosine (II) nucleosides, or two modified nucleosides wherein one is inosine and one is adenosine (Al or IA).
140. The oligomeric duplex of any one of claims 123-139, wherein none of the modified sugar moieties or sugar surrogates of the nucleosides of the second modified oligonucleotide comprises a fluorine.
141. The oligomeric duplex of any one of claims 123-139, wherein at least one of the modified sugar moieties or sugar surrogates of the second modified oligonucleotide comprises a fluorine and wherein fewer than 40%, fewer than 30%, fewer than 25%, fewer than 20%, fewer than 15%, fewer than 14%, fewer than 13%, fewer than 12%, fewer than 10%, or fewer than 5% of the nucleosides of the second modified oligonucleotide comprises a fluorine; and / or wherein fewer than 30%, fewer than 25%, fewer than 20%, fewer than 15 %, fewer than 14%, fewer than 13%, fewer than 12%, fewer than 10%, or fewer than 5% of the total nucleosides in the oligomeric duplex comprise a fluorine.
142. The oligomeric duplex of any one of claims 123-139, wherein two, three or four of the nucleosides of the second modified oligonucleotide independently comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine or no more than 4 nucleosides, no more than 3 nucleosides, no more than 2 nucleosides, or no more than 1 nucleoside of the second modified oligonucleotide comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine.
143. The oligomeric duplex of any one of claims 123-142, wherein two, three or four of the nucleosides of the first modified oligonucleotide independently comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine or no more than 4 nucleosides, no more than 3 nucleosides, no more than 2 nucleosides, or no more than 1 nucleoside of the first modified oligonucleotide comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine.
144. The oligomeric duplex of any one of claims 123-143, wherein no more than 1 nucleoside, no more than 2 nucleosides, or no more than 3 nucleosides within the sequence of the first modified oligonucleotide between and including the third and twenty -first nucleosides counting from the 5 ’ end of the modified oligonucleotide comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine.
145. The oligomeric duplex of any one of claims 123-144, wherein one or more nucleoside comprising a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine of the first modified oligonucleotide is / are independently selected from: i. the second nucleoside counting from the 5 ’ end, ii. the fourteenth and sixteenth nucleosides counting from the 5’ end, or iii. the second, fourteenth and sixteenth nucleosides counting from the 5’ end;wherein each modified sugar moiety comprising a fluorine or sugar surrogate comprising a fluorine is independently a 2’-fluoro sugar moiety or a 3’-fluoro-hexitol sugar moiety.
146. The oligomeric duplex of any one of claims 123-145, wherein none of the nucleosides of the second modified oligonucleotide is a 2 ’-deoxynucleoside and / or none of the nucleosides of the first modified oligonucleotide is a 2 ’-deoxynucleoside.
147. The oligomeric duplex of any one of claims 123-146, wherein all of the nucleosides of the second modified oligonucleotide comprise a modified ribosyl sugar moiety.
148. The oligomeric duplex of any one of claims 123-145 and 147, wherein one, two, or three of the nucleosides of the first modified oligonucleotide is / are a 2 ’-deoxynucleoside or wherein no more than 3, nor more than 2, or no more than one nucleoside(s) of the first modified oligonucleotide is / are a 2’- deoxynucleoside(s), or wherein only 3, only 2, or only one nucleoside(s) of the first modified oligonucleotide is / are a 2’-deoxynucleoside(s).
149. The oligomeric duplex of claim 148, wherein the fifth and seventh nucleosides counting from the 5’ end of the first modified oligonucleotide are 2’-deoxynucleosides, or wherein the sixth nucleoside counting from the 5’ end of the first modified oligonucleotide is a 2 ’-deoxynucleoside.
150. The oligomeric duplex of any one of claims 123-149, wherein:(a) the 5’- and 3 ’-terminal nucleosides, the nucleoside immediately 3’ of the 5’- terminal nucleoside, and the nucleoside immediately 5’ of the 3 ’-terminal nucleoside of the second modified oligonucleotide comprise a 2 ’-MOE sugar moiety, and / or(b) the 5’- and 3 ’-terminal nucleosides and the nucleoside immediately 5’ of the 3 ’-terminal nucleoside of the first modified oligonucleotide comprise a 2 ’-MOE sugar moiety, and / or(c) any nucleoside in the first and second modified oligonucleotides that does not comprise a fluorine or a 2’-MOE sugar moiety comprises a 2’-OMe sugar moiety.
151. The oligomeric duplex of any one of claims 123-149, wherein the 3’-terminal nucleoside of the first modified oligonucleotide comprises a 2’-OMe sugar moiety and / or the nucleoside immediately 5’ of the 3 ’-terminal nucleoside of the first modified oligonucleotide comprises a 2’-OMe sugar moiety and optionally the 5 ’-terminal nucleoside of the first modified oligonucleotide comprises a 2 ’-MOE sugar moiety.
152. The oligomeric duplex of any one of claims 123-151, wherein the first oligomeric compound comprises a stabilized phosphate group attached to the 5 ’-terminal nucleoside of the first modified oligonucleotide.
153. The oligomeric duplex of claim 152, wherein the stabilized phosphate group comprises a cyclopropyl phosphonate or a vinyl phosphonate.
154. The oligomeric duplex of any one of claims 123-153, wherein no more than four of the nucleosides of the first modified oligonucleotide comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine.
155. The oligomeric duplex of claim 154, wherein the first modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: efyyyfyyyyyyyfyfyyyyyee, efyyyfyyyyyyyfyfyyyyyyy, e[FHNA]yyyfyyyyyyyfyfyyyyyee, e[FHNA]yyyfyyyyyyyfyfyyyyyyy, efyyyfyyyyyyyfyfyyyyyey, e[FHNA]yydydyyyyfyfyfyyyyyyy and efyyyfyyyyyyyfyfyyyee; wherein each “d” represents a 2’-deoxy sugar moiety, each “y” represents a 2’-0Me sugar moiety, each “e” represents a 2’-M0E sugar moiety, each “f” represents a 2’-fluoro sugar moiety, and each “[FHNA]” represents a 3’-fluoro-hexitol sugar moiety.
156. The oligomeric duplex of any one of claims 123-153, wherein no more than three of the nucleosides of the first modified oligonucleotide comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine.
157. The oligomeric duplex of claim 156, wherein the first modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: efyyydyyyyyyyfyfyyyyyee, efyyydyyyyyyyfyfyyyyyyy, e[FHNA]yyydyyyyyyyfyfyyyyyee, e[FHNA]yyydyyyyyyyfyfyyyyyyy, efyydydyyyyyyfyfyyyyyee, efyydydyyyyyyfyfyyyyyyy, e [FHNA]yydydyyyyyyfyfyyyyyee, e [FHNA]yydydyyyyyyfyfyyyyyyy , efyyyyyyyyyyyfyfyyyyyee, efyyyfyyyyyyyfyyyyyyyyy, efyyyfyyyyyyyfydyyyyyee, efyyyfyyyyyyyfydyyyyyyy, efyyyfyyyyyyyfydyyyyyee, efyyyfyyyyyyyfydyyyyyyy, efyydydyyyyyyfyfyyyyye, efyydydyyyyyyfyfyyyyyy, efyyydyyyyyyyfyfyyyyye, efyyydyyyyyyyfyfyyyyyy, efyyyyyyyyyyyfyfyyyyye, efyyyyyyyyyyyfyfyyyyyy, efyydydyyyyyyfyfyyyyy, efyyydyyyyyyyfyfyyyyy, and efyyyyyyyyyyyfyfyyyyy; wherein each “d” represents a 2’-deoxy sugar moiety, each “y” represents a 2’- OMe sugar moiety, each “e” represents a 2’-M0E sugar moiety, each “f ’ represents a 2’-fluoro sugar moiety, and each “[FHNA]” represents a 3’ -fluoro -hexitol sugar moiety.
158. The oligomeric duplex of any one of claims 123-153, wherein no more than two of the nucleosides of the first modified oligonucleotide comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine.
159. The oligomeric duplex of claim 158, wherein the first modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: efyyyyyyyyyyyfyyyyyyyee, efyyyyyyyyyyyfyyyyyyyyy, e[FHNA]yyyyyyyyyyy[FHNA]yyyyyyyee, and e[FHNA]yyyyyyyyyyy[FHNA]yyyyyyyyy; wherein each “y” represents a 2’-0Me sugar moiety, each “e” represents a 2’-M0E sugar moiety, each “f ’ represents a 2’- fluoro sugar moiety, and each “[FHNA]” represents a 3’-fluoro-hexitol sugar moiety.
160. The oligomeric duplex of any one of claims 123-153, wherein only one of the nucleosides of the first modified oligonucleotide comprises a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine.
161. The oligomeric duplex of claim 160, wherein the first modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: efyyydyyyyyyydydyyyyyyy, efyyydyyyyyyydydyyyyyee,e[FHNA]yyydyyyyyyydydyyyyyyy, and e[FHNA]yyydyyyyyyydydyyyyyee; wherein each “d” represents a 2’-deoxy sugar moiety, each “y” represents a 2’-0Me sugar moiety, each “e” represents a 2’-M0E sugar moiety, each “f” represents a 2’-fluoro sugar moiety, and each “[FHNA]” represents a 3’-fluoro-hexitol sugar moiety.
162. The oligomeric duplex of any one of claims 123-158 and 160, wherein no more than two of the nucleosides of the first modified oligonucleotide are 2 ’-deoxynucleosides.
163. The oligomeric duplex of claim 162 wherein the first modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: efyydydyyyyyyfyfyyyyyee, efyydydyyyyyyfyfyyyyyyy, e[FHNA]yydydyyyyyyfyfyyyyyee, e[FHNA]yydydyyyyyyfyfyyyyyyy, efyydydyyyyyyfyfyyyyye, efyydydyyyyyyfyfyyyyyy, and efyydydyyyyyyfyfyyyyy; wherein each “d” represents a 2’-deoxy sugar moiety, each “y” represents a 2’-OMe sugar moiety, each “e” represents a 2 ’-MOE sugar moiety, each “f ’ represents a 2’-fluoro sugar moiety, and each “[FHNA]” represents a 3’ -fluoro -hexitol sugar moiety.
164. The oligomeric duplex of any one of claims 123-154, 156, 158 and 160, wherein only one of the nucleosides of the first modified oligonucleotide is a 2 ’-deoxynucleoside.
165. The oligomeric duplex of claim 164, wherein the first modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: efyyydyyyyyyyfyfyyyyyee, efyyydyyyyyyyfyfyyyyyyy, e[FHNA]yyydyyyyyyyfyfyyyyyee, e[FHNA]yyydyyyyyyyfyfyyyyyyy, eyyyfyyyyyyyfydyyyyyyy, efyyyfyyyyyyyfydyyyyyee, efyyy[FHNA]yyyyyyyfydyyyyyyy, e[FHNA]yyyfyyyyyyyfydyyyyyee, efyyydyyyyyyyfyfyyyyye, efyyydyyyyyyyfyfyyyyyy, and efyyydyyyyyyyfyfyyyyy; wherein each “d” represents a 2’-deoxy sugar moiety, each “y” represents a 2’-OMe sugar moiety, each “e” represents a 2’- MOE sugar moiety, each “f ’ represents a 2’-fluoro sugar moiety, and each “[FHNA]” represents a 3’-fluoro- hexitol sugar moiety.
166. The oligomeric duplex of any one of claims 123-154, wherein none of the nucleosides of the first modified oligonucleotide comprises a 2’-deoxy sugar moiety.
167. The oligomeric duplex of claim 166, wherein the first modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: efyyyyyyyyyyyfyfyyyyyee, efyyyfyyyyyyyfyyyyyyyyy, efyyyyyyyyyyyfyfyyyyye, efyyyyyyyyyyyfyfyyyyyy, and efyyyyyyyyyyyfyfyyyyy, wherein each “y” represents a 2’-OMe sugar moiety, each “e” represents a 2’-MOE sugar moiety, and each “f” represents a 2’- fluoro sugar moiety.
168. The oligomeric duplex of any one of claims 123-139 and 141-167, wherein no more than four of the nucleosides of the second modified oligonucleotide comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine.
169. The oligomeric duplex of claim 168, wherein the second modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: yyyyyyfyfffyyyyyyyyyy, eeyyyyfyfffyyyyyyyyee, yyyyyyfyfffyyyyyyyy, eeyyyyfyfffyyyyyyee, yyyyfyfffyyyyyyyyyy, and eeyyfyfffyyyyyyyyee; wherein each“y” represents a 2’-0Me sugar moiety, each “e” represents a 2’-M0E sugar moiety, and each “f” represents a 2 ’-fluoro sugar moiety.
170. The oligomeric duplex of any one of claims 123-139 and 141-167, wherein no more than three of the nucleosides of the second modified oligonucleotide comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine.
171. The oligomeric duplex of claim 170, wherein the second modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: eeyyyyfyfyfyyyyyyyyee and yyyyyyfyfyfyyyyyyyyyy; wherein each “y” represents a 2’-OMe sugar moiety, each “e” represents a 2’-MOE sugar moiety, and each “f” represents a 2’-fluoro sugar moiety.
172. The oligomeric duplex of any one of claims 123-139 and 141-167, wherein no more than two of the nucleosides of the second modified oligonucleotide comprise a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine.
173. The oligomeric duplex of claim 172, wherein the second modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: eeyyyyyyyffyyyyyyyyee, yyyyyyyyyffyyyyyyyyyy, eeyyyyyffyyyyyyyyee, and yyyyyyyffyyyyyyyyyy; wherein each “y” represents a 2’-OMe sugar moiety, each “e” represents a 2’-MOE sugar moiety, and each “f” represents a 2’-fluoro sugar moiety.
174. The oligomeric duplex of any one of claims 123-167, wherein none of the nucleosides of the second modified oligonucleotide comprises a modified sugar moiety comprising a fluorine or a sugar surrogate comprising a fluorine and wherein the second modified oligonucleotide has a sugar motif (5’ to 3’) selected from among: yyyyyyyyyyyyyyyyyyyyy, eeyyyyyyyyyyyyyyyyyee, yyyyyyyyyydyyyyyyyyyy, and eeyyyyyyyydyyyyyyyyee; wherein each “y” represents a 2’-OMe sugar moiety, each “e” represents a 2’- MOE sugar moiety, and each “d” represents a 2 ’-deoxy sugar moiety.
175. The oligomeric duplex of any one of claims 123-174, wherein one or more of the intemucleoside linkages of the first modified oligonucleotide is / are a modified intemucleoside linkage and / or wherein fewer than 50%, fewer than 40%, fewer than 30%, fewer than 20%, or fewer than 10% of the intemucleoside linkages of the first modified oligonucleotide are modified intemucleoside linkages.
176. The oligomeric duplex of any one of claims 123-175, wherein the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 5 ’ end of the first modified oligonucleotide, and the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 3 ’ end of the first modified oligonucleotide are phosphorothioate intemucleoside linkages.
177. The oligomeric duplex of any one of claims 123-175, wherein the first modified oligonucleotide has an intemucleoside linkage motif (5’ to 3’) selected from among: ssooooooooooooooooooss, ssooosooooooooooooooss, ssoososoooooooooooooss, ssoooooooooooooooooos, ssoooooooooooooooooo, and ssooooooooooooooooss; wherein each “o” represents a phosphodiester intemucleoside linkage and each “s” represents a phosphorothioate intemucleoside linkage.
178. The oligomeric duplex of any one of claims 123-177, wherein one or more of the intemucleoside linkages of the second modified oligonucleotide is / are a modified intemucleoside linkage(s).
179. The oligomeric duplex of any one of claims 123-178, wherein fewer than 50%, fewer than 40%, fewer than 30%, fewer than 20%, or fewer than 10% of the intemucleoside linkages of the second modified oligonucleotide are modified intemucleoside linkages.
180. The oligomeric duplex of any one of claims 123-179, wherein the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 5’ end of the second modified oligonucleotide, and the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 3 ’ end of the second modified oligonucleotide are phosphorothioate intemucleoside linkages.
181. The oligomeric duplex of any one of claims 123-180, wherein the second modified oligonucleotide has an intemucleoside linkage motif (5’ to 3’) selected from among: ssooooooooooooooooss, ssooooooosooooooooss, ssoooooozozoooooooss, and ssooooooooooooooss; wherein each “o” represents a phosphodiester intemucleoside linkage, each “s” represents a phosphorothioate intemucleoside linkage, and each ‘z’ represents a mesyl phosphoramidate intemucleoside linkage.
182. The oligomeric duplex of any one of claims 1-4, 12, 18, 19, 30-69, 72, 80, 105-115, 117-139, 152, 153, and 175-181, wherein the first modified oligonucleotide has a first sugar motif (1st) and the second modified oligonucleotide has a second sugar motif (2nd) and the first and second sugar motifs are selected from among the following combinations (5’ to 3’): 1st: efyydydyyyyyyfyfyyyyyee and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyydydyyyyyyfyfyyyyyyy and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyydydyyyyyyfyfyyyyyee and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyydydyyyyyyfyfyyyyyyy and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyyee and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyyyy and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyyyyyyyyyyfyfyyyyyee and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyyyyyyyyyyfyfyyyyyyy and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyydyyyyyyyfyfyyyyyee and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyydyyyyyyyfyfyyyyyyy and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyydyyyyyyyfyfyyyyyee and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyydyyyyyyyfyfyyyyyyy and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyydydyyyyyyfyfyyyyyee and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyydydyyyyyyfyfyyyyyyy and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyydydyyyyyyfyfyyyyyee and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyydydyyyyyyfyfyyyyyyy and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyydyyyyyyyfyfyyyyyee and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyydyyyyyyyfyfyyyyyyy and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyydyyyyyyyfyfyyyyyee and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyydyyyyyyyfyfyyyyyyy and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyyee and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyyyy and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyyyyyyyyyyfyfyyyyyee and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyyyyyyyyyyfyfyyyyyyy and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyye and 2nd:eeyyyyyyyffyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyyy and 2nd: yyyyyyyyyH'yyyyyyyyyy: 1st: efyyyyyyyyyyyfyfyyyyye and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyyyyyyyyyyfyfyyyyyy and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyye and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyyy and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyyyyyyyyyyfyfyyyyye and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyyyyyyyyyyfyfyyyyyy and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyydydyyyyyyfyfyyyyye and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyydydyyyyyyfyfyyyyyy and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyydydyyyyyyfyfyyyyye and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyydydyyyyyyfyfyyyyyy and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyydydyyyyyyfyfyyyyye and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyydydyyyyyyfyfyyyyyy and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyydydyyyyyyfyfyyyyye and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyydydyyyyyyfyfyyyyyy and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyydyyyyyyyfyfyyyyye and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyydyyyyyyyfyfyyyyyy and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyydyyyyyyyfyfyyyyye and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyydyyyyyyyfyfyyyyyy and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyydyyyyyyyfyfyyyyye and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyydyyyyyyyfyfyyyyyy and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyydyyyyyyyfyfyyyyye and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyydyyyyyyyfyfyyyyyy and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyy and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyy and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyyyyyyyyyyfyfyyyyy and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyy and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1stefyydydyyyyyyfyfyyyyy and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyydydyyyyyyfyfyyyyy and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyydydyyyyyyfyfyyyyy and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyydydyyyyyyfyfyyyyy and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyydyyyyyyyfyfyyyyy and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyydyyyyyyyfyfyyyyy and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyydyyyyyyyfyfyyyyy and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyydyyyyyyyfyfyyyyy and 2nd: yyyyyyfyfyfyyyyyyyyyy; wherein each “y” represents a 2’-0Me sugar moiety, each “e” represents a 2’-M0E sugar moiety, each “f ’ represents a 2’-fluoro sugar moiety, and each “d” represents a 2 ’-deoxy sugar moiety.
183. The oligomeric duplex of any one of claims 1-4, 12, 18, 19, 30-69, 72, 80, 105-115, 117-139, 152, 153, and 175-181, wherein the first modified oligonucleotide has a first sugar motif (1st) and the second modified oligonucleotide has a second sugar motif (2nd) and the first and second sugar motifs are selected from among the following combinations (5’ to 3’): 1st: efyydydyyyyyyfyfyyyyyee and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: efyydydyyyyyyfyfyyyyyyy and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: efyydydyyyyyyfyfyyyyyee and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: efyydydyyyyyyfyfyyyyyyy and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyyee and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyyyy and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: efyyyyyyyyyyyfyfyyyyyee and 2nd: yyyyyyfyfffyyyyyyyyyy; 1stefyyyyyyyyyyyfyfyyyyyyy and 2nd: eeyyyyfyfffyyyyyyyyee; 1st:efyyyyyyyyyyyfyfyyyyyee and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyyyy and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyyyyyyyyyyfyfyyyyyee and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyyyyyyyyyyfyfyyyyyyy and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyyee and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyyyyyyyyyyfyfyyyyyyy and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyyyyyyyyyyfyfyyyyyee and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyyyyyyyyyyfyfyyyyyyy and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyyyy and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyyfyyyyyyyfyfyyyyy66and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyyyy and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyyee and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyyfyyyyyyyfyfyyyyyyy and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyyfyyyyyyyfyfyyyyyee and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyyyy and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyyee and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyyfyyyyyyyfyfyyyee and 2nd: eeyyyyfyfffyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyy and 2nd: yyyyyyfyfffyyyyyyyy; 1st: efyyyfyyyyyyyfyfyyyee and 2nd: yyyyyyfyfffyyyyyyyy; 1st: efyyyfyyyyyyyfyfyyyyy and 2nd: eeyyyyfyfffyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyee and 2nd: eeyyyyffyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyy and 2nd: yyyyyyffyyyyyyyyyy; 1st: efyyyfyyyyyyyfyfyyyee and 2nd: yyyyyyffyyyyyyyyyy; 1st: efyyyfyyyyyyyfyfyyyyy and 2nd: eeyyyyffyyyyyyyyee; 1st: e[FHNA]yydydyyyyfyfyfyyyyyee and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyyey and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyyey and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: e[FHNA]yydydyyyyfyfyfyyyyyyy and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: e[FHNA]yydydyyyyfyfyfyyyyyee and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: e[FHNA]yydydyyyyfyfyfyyyyyyy and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: e[FHNA]yydydyyyyfyfyfyyyyyee and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: e[FHNA]yydydyyyyfyfyfyyyyyyy and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: e[FHNA]yydydyyyyfyfyfyyyyyee and 2nd: yyyyyyfyfyfyyyyyyyyyy; and 1st: e[FHNA]yydydyyyyfyfyfyyyyyyy and 2nd: eeyyyyfyfyfyyyyyyyyee, wherein each “y” represents a 2’-0Me sugar moiety, each “e” represents a 2’-M0E sugar moiety, each “f” represents a 2’-fluoro sugar moiety, each “[FHNA]” represents a 3’-fluoro-hexitol sugar moiety, and each “d” represents a 2’-deoxy sugar moiety.
184. The oligomeric duplex of any one of claims 1-4, 12, 18, 19, 30-69, 72, 80, 105-115, 117-139,152, 153, and 175-181, wherein the first modified oligonucleotide has a first sugar motif (1st) and the second modified oligonucleotide has a second sugar motif (2nd) and the first and second sugar motifs are selected from among the following combinations (5’ to 3’): 1st: efyyyfyyyyyyyfyfyyyyyyy and 2nd: yyyyyyfyfffyyyyyyyyyy; 1stefyyyfyyyyyyyfyfyyyyyee and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyyee and 2nd: yyyyyyfyfffyyyyyyyyyy; and 1st: efyyyfyyyyyyyfyfyyyyyyy and 2nd: eeyyyyfyfffyyyyyyyyee, wherein each “y” represents a 2’-OMe sugar moiety, each “e” represents a 2’-MOE sugar moiety, and each “f” represents a 2 ’-fluoro sugar moiety.
185. The oligomeric duplex of any one of claims 1-4, 12, 18, 19, 30-69, 72, 80, 105-115, 117-139, 152, 153, and 175-181, wherein the first modified oligonucleotide has a first sugar motif (1st) and thesecond modified oligonucleotide has a second sugar motif (2nd) and the first and second sugar motifs are selected from among the following combinations (5’ to 3’): 1st: efyyyfyyyyyyyfyfyyyyyyy and 2nd: yyyyyyyyyyyyyyyyyyyyy; 1st: efyyyfyyyyyyyfyfyyyyyee and 2nd: eeyyyyyyyyyyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyyyy and 2nd: eeyyyyyyyyyyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyyee and 2nd: yyyyyyyyyyyyyyyyyyyyy; 1stefyyyfyyyyyyyfyfyyyyyyy and 2nd: yyyyyyyyyydyyyyyyyyyy; 1st: efyyyfyyyyyyyfyfyyyyyee and 2nd: eeyyyyyyyydyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyyyy and 2nd: eeyyyyyyyydyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyyee and 2nd: yyyyyyyyyydyyyyyyyyyy; 1st: efyyyyyyyyyyyfyyyyyyyee and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: efyyyyyyyyyyyfyyyyyyyyy and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: efyyyyyyyyyyyfyyyyyyyee and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: efyyyyyyyyyyyfyyyyyyyyy and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: efyyyyyyyyyyyfyyyyyyyee and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyyyyyyyyyyfyyyyyyyyy and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyyyyyyyyyyfyyyyyyyee and 2nd: yyyyyyfyfyfyyyyyyyyyy; 1st: efyyyyyyyyyyyfyyyyyyyyy and 2nd: eeyyyyfyfyfyyyyyyyyee; 1st: efyyydyyyyyyyfyfyyyyyee and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: efyyydyyyyyyyfyfyyyyyyy and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: efyyydyyyyyyyfyfyyyyyee and 2nd: yyyyyyfyfffyyyyyyyyyy; 1stefyyydyyyyyyyfyfyyyyyyy and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyee and 2nd: eeyyfyfffyyyyyyyyee; 1st: efyyyfyyyyyyyfyfyyyyy and 2nd: yyyyfyfffyyyyyyyyyy; 1st: efyyyfyyyyyyyfyfyyyee and 2nd: yyyyfyfffyyyyyyyyyy; 1st: efyyyfyyyyyyyfyfyyyyy and 2nd: eeyyfyfffyyyyyyyyee; 1st: efyyyfyyyyyyyfydyyyyyee and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: efyyyfyyyyyyyfydyyyyyyy and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: efyyyfyyyyyyyfydyyyyyee and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: efyyyfyyyyyyyfydyyyyyyy and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: e[FHNA]yyyfyyyyyyyfyfyyyyyee and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: e[FHNA]yyyfyyyyyyyfyfyyyyyyy and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: e[FHNA]yyyfyyyyyyyfyfyyyyyee and 2nd: yyyyyyfyfffyyyyyyyyyy; and 1st: e[FHNA]yyyfyyyyyyyfyfyyyyyyy and 2nd: eeyyyyfyfffyyyyyyyyee, wherein each “y” represents a 2’-OMe sugar moiety, each “e” represents a 2’-MOE sugar moiety, each “f” represents a 2’-fluoro sugar moiety, each “[FHNA]” represents a 3’-fluoro-hexitol sugar moiety, and each “d” represents a 2 ’-deoxy sugar moiety.
186. The oligomeric duplex of any one of claims 1-4, 12, 18, 19, 30-69, 72, 80, 105-115, 117-139, 152, 153, and 175-181, wherein the first modified oligonucleotide has a first sugar motif (1st) and the second modified oligonucleotide has a second sugar motif (2nd) and the first and second sugar motifs are selected from among the following combinations (5’ to 3’): 1st: efyyyyyyyyyyyfyyyyyyyee and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyyyyyyyyyyfyyyyyyyyy and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyyyyyyyyyyfyyyyyyyee and 2nd: yyyyyyyyyffyyyyyyyyyy; 1st: efyyyyyyyyyyyfyyyyyyyyy and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyyfyyyyyyyfyyyyyyyee and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: efyyyfyyyyyyyfyyyyyyyyy and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: efyyyfyyyyyyyfyyyyyyyee and 2nd: yyyyyyfyfffyyyyyyyyyy; 1st: efyyyfyyyyyyyfyyyyyyyyy and 2nd: eeyyyyfyfffyyyyyyyyee; 1st: efyyyfyyyyyyyfyyyyyyyee and 2nd: eeyyyyyyyffyyyyyyyyee; 1st: efyyyfyyyyyyyfyyyyyyyyy and 2nd:yyyyyyyyyffyyyyyyyyyy; 1st: efyyyfyyyyyyyfyyyyyyyee and 2nd: yyyyyyfyfffyyyyyyyyyy; and 1st: efyyyfyyyyyyyfyyyyyyyyy and 2nd: eeyyyyfyfffyyyyyyyyee, wherein each “y” represents a 2’-0Me sugar moiety, each “e” represents a 2 ’-MOE sugar moiety, and each “f” represents a 2 ’-fluoro sugar moiety.
187. The oligomeric duplex of any one of claims 123-186, wherein the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 5 ’ end of the first modified oligonucleotide, and the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 3 ’ end of the first modified oligonucleotide are phosphorothioate intemucleoside linkages and wherein all other intemucleoside linkages of the first modified oligonucleotide are phosphodiester intemucleoside linkages.
188. The oligomeric duplex of any one of claims 123-187, wherein the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 5 ’ end of the second modified oligonucleotide, and the intemucleoside linkages between the first and second nucleosides and the second and third nucleosides counting from the 3 ’ end of the second modified oligonucleotide are phosphorothioate intemucleoside linkages and wherein all other intemucleoside linkages of the second modified oligonucleotide are phosphodiester intemucleoside linkages.
189. The oligomeric duplex of any one of claims 123-188, wherein the nucleobase sequence of the first modified oligonucleotide comprises or consists of the nucleobase sequence of any one of SEQ ID NOs: 967, 968, 971, 972, 974, 975, 1033-1038, 1254-1255, or 1258-1287.
190. The oligomeric duplex of any one of claims 1-189, wherein a cytosine nucleobase in the first and / or second modified oligonucleotide is optionally 5-methylcytosine.
191. The oligomeric duplex of any one of claims 123-190, wherein the oligomeric duplex comprises a conjugate group comprising a conjugate moiety and a conjugate linker.
192. The oligomeric duplex of claim 191, wherein the conjugate moiety comprises an active dmg substance, an aliphatic chain, a lipid, a peptide, a protein, a hydrocarbon, a polyamine, a polyamide, a polyether, a thioether, an aptamer, an antibody, an antibody fragment, a vitamin, a fatty acid, a carbohydrate, an intercalator or a reporter molecule.
193. The oligomeric duplex of claim 191, wherein the conjugate group comprises a C22 alkyl, C20 alkyl, C17 alkyl, C16 alkyl, CIO alkyl, C21 alkyl, C19 alkyl, C18 alkyl, C15 alkyl, C14 alkyl, C13 alkyl, C12 alkyl, Cl l alkyl, C9 alkyl, C8 alkyl, C7 alkyl, C6 alkyl, or C5 alkyl, wherein the alkyl chain optionally has one or more unsaturated bonds.
194. The oligomeric duplex of claim 191, wherein the conjugate group comprises a 6- palmitamidohexyl moiety or a 2-(hydroxymethyl)-6-palmitamidohexyl moiety.
195. The oligomeric duplex of claim 191, wherein the oligomeric duplex comprises a conjugate moiety that binds type 1 transferrin receptor (TfRl).
196. The oligomeric duplex of claim 195, wherein the conjugate moiety is selected from an antibody or fragment thereof, a protein or peptide, and an aptamer capable of binding TfRl .
197. The oligomeric duplex of claim 196, wherein the conjugate moiety is a cyclic protein or cyclic peptide.
198. The oligomeric duplex of claim 195, wherein the conjugate group comprises a bicycle ligand and a conjugate linker.
199. The oligomeric duplex of claim 198, wherein the bicycle ligand comprises a peptide consisting of 13-22 linked amino acids or amino acid mimetics and a molecular scaffold, wherein each of a first, a second, and a third amino acid of the peptide comprises a reactive group, each of which separately forms a bond with the molecular scaffold, thereby forming two peptide loops attached to the molecular scaffold.
200. The oligomeric duplex of claim 199 wherein the bicycle ligand comprises an amino acid sequence selected from any one of SEQ ID NO: 1062-1253.
201. The oligomeric duplex of any one of claims 198-200, wherein the conjugate linker comprises a (bicyclo[6.1.0]nonyne)-formyl (BCN) moiety.
202. The oligomeric duplex of any one of claims 198-200, wherein the conjugate linker comprises a 6-(BCN-carbamate)-2-(hydroxymethyl)hexyl phosphoryl moiety or a 6-(BCN-carbamate)hexyl phosphoryl moiety.
203. The oligomeric duplex of any one of claims 123-190, comprising a conjugate group consisting of a conjugate moiety and a conjugate linker wherein the conjugate linker comprises a 6-(BCN- carbamate)-2-(hydroxymethyl)hexyl phosphoryl moiety or a 6-(BCN-carbamate)hexyl phosphoryl moiety.
204. The oligomeric duplex of any one of claims 123-190, comprising a bicycle ligand comprising a peptide having an amino acid sequence selected from any one of SEQ ID NOs: 1062-1253 and wherein each cysteine forms a covalent bond with the molecular scaffold l,T,l"-(l,3,5-triazinane-l,3,5-triyl)tris(2- bromoethanone) (TATB) or the molecular scaffold is l,T,l"-(l,3,5-triazinane-l,3,5-triyl)triprop-2-en-l-one (TATA).
205. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: vPTesUfsUyo yo yoGdo yoUyoGyo yoGyoAyoCyoAfoGyoAfo yo yoUyoUyoGys es e (SEQ ID NO: 1033), wherein:A = an adenine nucleobase,C = a cytosine nucleobase,G = a guanine nucleobase,T = a thymine nucleobase,U = a uracil nucleobase, d = a 2 ’-deoxy sugar moiety, e = a 2 ’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety,o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, and vP = a 5’ vinyl phosphonate group.
206. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation:mCesAesAyoUyoUyoUyoCyoUyoGyoUfoCfoUyoCyoAyoUyoCyoUyoUyoAysAesAe (SEQ ID NO: 1027), wherein: A = an adenine nucleobase, mC = a 5-methyl cytosine nucleobase, C = a cytosine nucleobase, G = a guanine nucleobase, U = a uracil nucleobase, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, and s = a phosphorothioate internucleoside linkage.
207. An oligomeric compound comprising a conjugated modified oligonucleotide according to the following chemical notation: [X]n-mCesAesAyoUyoUyoUyoCyoUyoGyoUfoCfoUyoCyoAyoUyoCyoUyoUyoAysAesAe-[X]k(SEQ ID NO: 1039), wherein: mC = a 5-methyl cytosine nucleobase, C = a cytosine nucleobase, A = an adenine nucleobase, G = a guanine nucleobase, U = a uracil nucleobase, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, [X] = a conjugate group comprising a bicycle ligand, and n and k are 0 or 1, wherein if n=1 then k=0, and if n=0 then k=1.
208. An oligomeric duplex comprising the oligomeric compound according to claim 205 and the oligomeric compound according to claim 206.
209. An oligomeric duplex comprising the oligomeric compound according to claim 205 and the oligomeric compound according to claim 207.
210. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: vP-TesUfsUyoAyoAdoGyoAdoUyoGyoAyoGyoAyoCyoAfoGyoAfoAyoAyoUyoUyoGysAesAe(SEQ ID NO: 1034), wherein: A = an adenine nucleobase, C = a cytosine nucleobase, G = a guanine nucleobase, T = a thymine nucleobase, U = a uracil nucleobase, d = a 2’-deoxy sugar moiety, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, and vP = a 5’ vinyl phosphonate group.
211. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: CesAesAyoUyoUyoUyoCfoUyoGfoUyoCfoUyoCyoAyoUyoCyoUyoUyoAysAesAe(SEQ ID NO: 1028), wherein: A = an adenine nucleobase, C = a cytosine nucleobase, G = a guanine nucleobase, U = a uracil nucleobase, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-Ome sugar moiety, o = a phosphodiester internucleoside linkage, and s = a phosphorothioate internucleoside linkage.
212. An oligomeric compound comprising a conjugated modified oligonucleotide according to the following chemical notation: [X]n-CesAesAyoUyoUyoUyoCfoUyoGfoUyoCfoUyoCyoAyoUyoCyoUyoUyoAysAesAe-[X]k(SEQ ID NO: 1040), wherein: C = a cytosine nucleobase, A = an adenine nucleobase, G = a guanine nucleobase,U = a uracil nucleobase, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-Ome sugar moiety, o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, [X] = a conjugate group comprising a bicycle ligand, and n and k are 0 or 1, wherein if n=1 then k=0, and if n=0 then k=1.
213. An oligomeric duplex comprising an oligomeric compound of claim 210 and an oligomeric compound of claim 211.
214. An oligomeric duplex comprising an oligomeric compound of claim 210 and an oligomeric compound of claim 212.
215. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: vPTesAfsUyoAyoAyoAdoUyoAyoGyoAyoUyoUyoCyoUfoGyoUfoAyoGyoCyoUyoUysAesAe(SEQ ID NO: 1035), wherein: A = an adenine nucleobase, C = a cytosine nucleobase, G = a guanine nucleobase, T = a thymine nucleobase, U = a uracil nucleobase, d = a 2’-deoxy sugar moiety, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, and vP = a 5’ vinyl phosphonate group.
216. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: AesAesGyoCyoUyoAyoCyoAyoGyoAfoAfoUyoCyoUyoAyoUyoUyoUyoAysTesAe(SEQ ID NO: 1029), wherein: A = an adenine nucleobase, C = a cytosine nucleobase, G = a guanine nucleobase, T = a thymine nucleobase, U = a uracil nucleobase,e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, and s = a phosphorothioate internucleoside linkage.
217. An oligomeric compound comprising a conjugated modified oligonucleotide according to the following chemical notation: [X]n- AesAesGyoCyoUyoAyoCyoAyoGyoAfoAfoUyoCyoUyoAyoUyoUyoUyoAysTesAe-[X]k(SEQ ID NO: 1041), wherein: C = a cytosine nucleobase, A = an adenine nucleobase, G = a guanine nucleobase, T = a thymine nucleobase, U = a uracil nucleobase, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, [X] = a conjugate group comprising a bicycle ligand, and n and k are 0 or 1, wherein if n=1 then k=0, and if n=0 then k=1.
218. An oligomeric duplex comprising an oligomeric compound of claim 215 and an oligomeric compound of claim 216.
219. An oligomeric compound comprising an oligomeric compound of claim 215 and an oligomeric compound of claim 217.
220. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: vPTesAfsUyoAyoAdoAyoTdoAyoGyoAyoUyoUyoCyoUfoGyoUfoAyoGyoCyoUyoUysAesAe(SEQ ID NO: 1036), wherein: A = an adenine nucleobase, C = a cytosine nucleobase, G = a guanine nucleobase, T = a thymine nucleobase, U = a uracil nucleobase, d = a 2’-deoxy sugar moiety, e = a 2’-MOE sugar moiety,f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, and vP = a 5’ vinyl phosphonate group.
221. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: AesAesGyoCyoUyoAyoCfoAyoGfoAyoAfoUyoCyoUyoAyoUyoUyoUyoAysUesAe(SEQ ID NO: 1030), wherein: A = an adenine nucleobase, C = a cytosine nucleobase, G = a guanine nucleobase, U = a uracil nucleobase, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, and s = a phosphorothioate internucleoside linkage.
222. An oligomeric compound comprising a conjugated modified oligonucleotide according to the following chemical notation: [X]n-AesAesGyoCyoUyoAyoCfoAyoGfoAyoAfoUyoCyoUyoAyoUyoUyoUyoAysUesAe-[X]k(SEQ ID NO: 1042), wherein: C = a cytosine nucleobase, A = an adenine nucleobase, G = a guanine nucleobase, U = a uracil nucleobase, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, [X] = a conjugate group comprising a bicycle ligand, and n and k are 0 or 1, wherein if n=1 then k=0, and if n=0 then k=1.
223. An oligomeric duplex comprising an oligomeric compound of claim 220 and an oligomeric compound of claim 221.
224. An oligomeric duplex comprising an oligomeric compound of claim 220 and an oligomeric compound of claim 222.
225. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: vPTesUfsAyoAyoGyoTdoUyoUyoUyoAyoGyoUyoCyoUfoUyoAfoAyoUyoCyoUyoUysAesAe(SEQ ID NO: 1037), wherein: A = an adenine nucleobase, C = a cytosine nucleobase, G = a guanine nucleobase, T = a thymine nucleobase, U = a uracil nucleobase, d = a 2’-deoxy sugar moiety, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, and vP = a 5’ vinyl phosphonate group.
226. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: AesAesGyoAyoUyoUyoAyoAyoGyoAfoCfoUyoAyoAyoAyoAyoCyoUyoUysAesAe(SEQ ID NO: 1031), wherein: A = an adenine nucleobase, C = a cytosine nucleobase, G = a guanine nucleobase, U = a uracil nucleobase, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, and s = a phosphorothioate internucleoside linkage.
227. An oligomeric compound comprising a conjugated modified oligonucleotide according to the following chemical notation: [X]n-AesAesGyoAyoUyoUyoAyoAyoGyoAfoCfoUyoAyoAyoAyoAyoCyoUyoUysAesAe-[X]k(SEQ ID NO: 1043), wherein: C = a cytosine nucleobase, A = an adenine nucleobase, G = a guanine nucleobase,U = a uracil nucleobase, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, [X] = a conjugate group comprising a bicycle ligand, and n and k are 0 or 1, wherein if n=1 then k=0, and if n=0 then k=1.
228. An oligomeric duplex comprising the modified oligonucleotide according to claim 225 and the modified oligonucleotide according to claim 226.
229. An oligomeric duplex comprising the modified oligonucleotide according to claim 225 and the conjugate according to claim 227.
230. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: vPTesUfsAyoAyoGdoUyoTdoUyoUyoAyoGyoUyoCyoUfoUyoAfoAyoUyoCyoUyoUysAesAe(SEQ ID NO: 1038), wherein: A = an adenine nucleobase, C = a cytosine nucleobase, G = a guanine nucleobase, T = a thymine nucleobase, U = a uracil nucleobase, d = a 2’-deoxy sugar moiety, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, and vP = a 5’ vinyl phosphonate group.
231. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: AesAesGyoAyoUyoUyoAfoAyoGfoAyoCfoUyoAyoAyoAyoAyoCyoUyoUysAesAe(SEQ ID NO: 1032), wherein: A = an adenine nucleobase, C = a cytosine nucleobase, G = a guanine nucleobase, U = a uracil nucleobase, e = a 2’-MOE sugar moiety,f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, and s = a phosphorothioate internucleoside linkage.
232. An oligomeric compound comprising a conjugated modified oligonucleotide according to the following chemical notation: [X]n-AesAesGyoAyoUyoUyoAfoAyoGfoAyoCfoUyoAyoAyoAyoAyoCyoUyoUysAesAe-[X]k(SEQ ID NO: 1044), wherein: C = a cytosine nucleobase, A = an adenine nucleobase, G = a guanine nucleobase, U = a uracil nucleobase, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, [X] = a conjugate group comprising a bicycle ligand, and n and k are 0 or 1, wherein if n=1 then k=0, and if n=0 then k=1.
233. An oligomeric duplex comprising an oligomeric compound of claim 230 and an oligomeric compound of claim 231.
234. An oligomeric duplex comprising an oligomeric compound of claim 230 and an oligomeric compound of claim 232.
235. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: vPTesAfsUyoAyoAyoAyoUyoAyoGyoAyoUyoUyoCyoUfoGyoUfoAyoGyoCyoUyoUysAesAe(SEQ ID NO: 1255), wherein: A = an adenine nucleobase, C = a cytosine nucleobase, G = a guanine nucleobase, T = a thymine nucleobase, U = a uracil nucleobase, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, andvP = a 5’ vinyl phosphonate group.
236. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: AesAesGyoCyoUyoAyoCyoAyoGyoAfoAfoUyoCyoUyoAyoUyoUyoUyoAysTesAe(SEQ ID NO: 1029), wherein: A = an adenine nucleobase, C = a cytosine nucleobase, G = a guanine nucleobase, U = a uracil nucleobase, T = a thymine nucleobase, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, and s = a phosphorothioate internucleoside linkage.
237. An oligomeric compound comprising a conjugated modified oligonucleotide according to the following chemical notation: [X]n-AesAesGyoCyoUyoAyoCyoAyoGyoAfoAfoUyoCyoUyoAyoUyoUyoUyoAysTesAe-[X]k(SEQ ID NO: 1041), wherein: C = a cytosine nucleobase, A = an adenine nucleobase, G = a guanine nucleobase, U = a uracil nucleobase, T = a thymine nucleobase, e = a 2’-MOE sugar moiety, f = a 2’-fluoro sugar moiety, y = a 2’-OMe sugar moiety, o = a phosphodiester internucleoside linkage, s = a phosphorothioate internucleoside linkage, [X] = a conjugate group comprising a bicycle ligand, and n and k are 0 or 1, wherein if n=1 then k=0, and if n=0 then k=1.
238. An oligomeric duplex comprising the oligomeric compound according to claim 235 and the oligomeric compound according to claim 236.
239. An oligomeric duplex comprising the oligomeric compound according to claim 235 and the oligomeric compound according to claim 237.
240. The oligomeric duplex of any one of claims 123-190, 209, 214, 219, 224, 229, 234, 239, or the oligomeric compound of any one of claims 207, 212, 217, 222, 227, 232, or 237, comprising a bicycle ligand or conjugate group having the following structure:or a salt thereof, wherein Q is N3(BCY17901, SEQ ID NO: 1045), NH2(BCY21757, SEQ ID NO: 1202), SH (BCY21758, SEQ ID NO: 1203), or a conjugate linker, or a conjugate linker covalently connected to an oligonucleotide.
241. The oligomeric duplex or oligomeric compound of claim 240, wherein Q is N3or a conjugate linker.
242. The oligomeric duplex of any one of claims 123-190, 209, 214, 219, 224, 229, 234, 239, or the oligomeric compound of any one of claims 207, 212, 217, 222, 227, 232, or 237, comprising a conjugate group having the following structure:
243. The oligomeric duplex of any one of claims 123-190, 209, 214, 219, 224, 229, 234, 239, or the oligomeric compound of any one of claims 207, 212, 217, 222, 227, 232, or 237, comprising a conjugate group having the following structure:
244. The oligomeric duplex or oligomeric compound of any one of claims 191-243, wherein the conjugate group is attached to the second modified oligonucleotide.
245. The oligomeric duplex or compound of any one of claims 191-243, wherein the conjugate group is attached to the 5’- or 3’- end of the second modified oligonucleotide.
246. The oligomeric duplex or oligomeric compound of any one of claims 191-243, wherein the conjugate group is attached to the 5 ’-terminal nucleoside of the second modified oligonucleotide.
247. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1033 and SEQ ID NO: 1027), or a salt thereof.
248. The oligomeric duplex of claim 247, which is the sodium salt or potassium salt.
249. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1033 and SEQ ID NO: 1027).
250. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1033 and SEQ ID NO: 1039), or a salt thereof.
251. The oligomeric duplex of claim 250, which is the sodium salt or potassium salt.
252. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1033 and SEQ ID NO: 1039).
253. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1034 and SEQ ID NO: 1028), or a salt thereof.
254. The oligomeric duplex of claim 253, which is the sodium salt or potassium salt.
255. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1034 and SEQ ID NO: 1028).
256. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1034 and SEQ ID NO: 1040), or a salt thereof.
257. The oligomeric duplex of claim 256, which is the sodium salt or potassium salt.
258. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1034 and SEQ ID NO: 1040).
259. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1035 and SEQ ID NO: 1029), or a salt thereof.
260. The oligomeric duplex of claim 259, which is the sodium salt or potassium salt.
261. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1035 and SEQ ID NO: 1029).
262. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1035 and SEQ ID NO: 1041), or a salt thereof.
263. The oligomeric duplex of claim 262, which is the sodium salt or potassium salt.
264. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1035 and SEQ ID NO: 1041).
265. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1036 and SEQ ID NO: 1030), or a salt thereof.
266. The oligomeric duplex of claim 265, which is the sodium salt or potassium salt.
267. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1036 and SEQ ID NO: 1030).
268. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1036 and SEQ ID NO: 1042), or a salt thereof.
269. The oligomeric duplex of claim 268, which is the sodium salt or potassium salt.
270. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1036 and SEQ ID NO: 1042).
271. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1037 and SEQ ID NO: 1031), or a salt thereof.
272. The oligomeric duplex of claim 271, which is the sodium salt or potassium salt.
273. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1037 and SEQ ID NO: 1031).
274. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1037 and SEQ ID NO: 1043), or a salt thereof.
275. The oligomeric duplex of claim 274, which is the sodium salt or potassium salt.
276. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1037 and SEQ ID NO: 1043).
277. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1038 and SEQ ID NO: 1032), or a salt thereof.
278. The oligomeric duplex of claim 277, which is the sodium salt or potassium salt.
279. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1038 and SEQ ID NO: 1032).
280. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1038 and SEQ ID NO: 1044), or a salt thereof.
281. The oligomeric duplex of claim 280, which is the sodium salt or potassium salt.
282. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1038 and SEQ ID NO: 1044).
283. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1255 and SEQ ID NO: 1029), or a salt thereof.
284. The oligomeric duplex of claim 283, which is the sodium salt or potassium salt.
285. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1255 and SEQ ID NO: 1029).
286. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1255 and SEQ ID NO: 1041), or a salt thereof.
287. The oligomeric duplex of claim 286, which is the sodium salt or potassium salt.
288. An oligomeric duplex according to the following chemical structure:(SEQ ID NO: 1255 and SEQ ID NO: 1041).
289. A population of oligomeric duplexes or oligomeric compounds of any one of claims 1-288, wherein the population is enriched for first and / or second modified oligonucleotides comprising at least one particular phosphorothioate intemucleoside linkage having a particular stereochemical configuration.
290. The population of claim 289, wherein the population is enriched for first and / or second modified oligonucleotides comprising at least one particular phosphorothioate intemucleoside linkage having the (Sp) or (Rp) configuration.
291. The oligomeric duplex or oligomeric compound of any one of claims 1-288, wherein the first modified oligonucleotide consists of 23 linked nucleosides and the second modified oligonucleotide consists of 21 linked nucleosides.
292. An antisense compound comprising or consisting of an oligomeric duplex or oligomeric compound of any one of claims 1-288.
293. The antisense compound of claim 292, wherein the antisense compound is an RNAi agent capable of reducing the amount of PLN nucleic acid through the activation of RISC / Ago2.
294. A pharmaceutical composition comprising the oligomeric duplex or oligomeric compound of any one of claims 1-288 or 291, the population of any one of claims 289-290, or the antisense compound of claim 292 or claim 293, and a pharmaceutically acceptable diluent or carrier.
295. The pharmaceutical composition of claim 294, wherein the pharmaceutically acceptable diluent is water or phosphate-buffered saline.
296. The pharmaceutical composition of claim 295, wherein the pharmaceutical composition consists essentially of the oligomeric duplex, oligomeric compound or the antisense compound, and water or phosphate-buffered saline.
297. A method of decreasing the amount of PLN RNA and / or PLN protein in a cell, tissue, organ or subject, comprising contacting the cell, tissue, organ or subject with the oligomeric duplex or oligomeric compound of any one of claims 1-288 or 291, the population of any one of claims 289-290, or the antisense compound of claim 292 or claim 293, or the pharmaceutical composition of any one of claims 294-296.
298. The method of claim 297, wherein the cell is a muscle cell and / or a cardiac cell.
299. A method comprising administering to a subject the oligomeric duplex or oligomeric compound of any one of claims 1-288 or 291, the population of any one of claims 289-290, or the antisense compound of claim 292 or claim 293, or the pharmaceutical composition of any one of claims 294-296; wherein the subject has or is at risk for developing a cardiovascular or cardiac injury, disease, condition or disorder, cardiomyopathy, cardiac arrythmia, and / or heart failure.
300. A method of preventing or treating a disease, disorder, condition or injury associated with cardiac calcium misregulation, or postponing a symptom of a disease, disorder or condition associated with a damaged, weakened and / or overworked heart, comprising administering to a subject having, or at risk of having, a disease, disorder or condition associated with cardiac calcium misregulation a therapeutically effective amount of the oligomeric duplex or oligomeric compound of any one of claims 1-288 or 291, thepopulation of any one of claims 289-290, or the antisense compound of claim 292 or claim 293, or the pharmaceutical composition of any one of claims 294-296; wherein the disease, disorder, condition or injury is selected from a cardiac or cardiovascular disease, disorder, condition or injury, a cardiomyopathy, cardiac arrythmia, and / or heart failure.
301. A method of preventing or treating a cardiac or cardiovascular disease, disorder, condition or injury associated with heart failure, or postponing a symptom of heart failure, comprising administering to a subject having, or at risk of having, a cardiac or cardiovascular disease, disorder, condition or injury a therapeutically effective amount of the oligomeric duplex or oligomeric compound of any one of claims 1- 288 or 291, the population of any one of claims 289-290, or the antisense compound of claim 292 or claim 293, or the pharmaceutical composition of any one of claims 294-296; wherein the disease, disorder, condition or injury is a cardiomyopathy, cardiac arrythmia, and / or heart failure.
302. A method of decreasing the amount of PLN RNA and / or PLN protein in the heart of a subject having or at risk of developing a disease, disorder or condition associated with a damaged, weakened and / or overworked heart, comprising administering to a subject having, or at risk of having, a disease, disorder or condition associated with a damaged, weakened and / or overworked heart a therapeutically effective amount of the oligomeric duplex or oligomeric compound of any one of claims 1-288 or 291, the population of any one of claims 289-290, or the antisense compound of claim 292 or claim 293, or the pharmaceutical composition of any one of claims 294-296; wherein the disease, disorder, condition or injury is a cardiomyopathy, cardiac arrythmia, and / or heart failure.
303. The method of any one of claims 297-302, wherein the amount of PLN RNA and / or PLN protein in cardiac muscle of the subject is decreased.
304. The method of any one of claims 297-302, wherein the disease, disorder or condition is cardiomyopathy or arrhythmia.
305. The method of claim 304, wherein the cardiomyopathy is genetic cardiomyopathy.
306. The method of claim 305, wherein the genetic cardiomyopathy is associated with PLN p.Argl4del, Arg9Cys (R9C), or Arg25Cys (R25C) genetic mutations.
307. The method of claim 304, wherein the cardiomyopathy is dilated cardiomyopathy (DCM).
308. The method of claim 307 wherein the DCM is genetic DCM.
309. The method of claim 308, wherein the genetic DCM is associated with TTN, LMNA,RBM20, SCN5A, MYH7, TNNT2, or TPM1 mutations.
310. The method of claim 307, wherein the DCM is arrhythmogenic DCM.
311. The method of any one of claims 299-303, wherein the heart failure is heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), acute heart failure, or worsening of chronic heart failure.
312. The method of claim 304, wherein the arrhythmia is ventricular tachycardia (vtac) or ventricular fibrillation (vfib).
313. The method of claim 300 or claim 301, wherein the symptom of a disease, disorder or condition associated with a damaged, weakened and / or overworked heart, or heart failure is reduced myocardial contractile function and / or impaired relaxation of the heart.
314. The method of any one of claims 299-313, wherein the method prevents or slows progression of damaged, weakened and / or overworked heart effects and / or heart failure.
315. The method of any one of claims 299-313, wherein administering of the oligomeric duplex or oligomeric compound of any one of claims 1-288 or 291, the population of any one of claims 289-290, or the antisense compound of claim 292 or claim 293, or the pharmaceutical composition of any one of claims 294- 296 improves cardiac function, cardiovascular death, cardiac dilation, cardiac fibrosis, low voltage ECG, diastolic calcium uptake, ejection fraction (EF), left ventricular ejection fraction (LVEF), left ventricular end systolic volume (LVESV), left ventricular end diastolic volume (LVEDV), mitral valve flow profile, left ventricle (LV) strain, left ventricle (LV) strain rate, infarct size, heart failure hospitalization, 6 minute walk test (6MWT), the Kansas City Cardiomyopathy Questionnaire Score (KCCQS), heart rate, or heart rhythm in the subject.
316. The method of any one of claims 297-315, wherein the oligomeric duplex or oligomeric compound of any one of claims 1-288 or 291, the population of any one of claims 289-290, or the antisense compound of claim 292 or claim 293, or the pharmaceutical composition of any one of claims 294-296 comprises a conjugate moiety having affinity for a transferrin receptor.
317. The method any one of claims 297-315, wherein the oligomeric duplex or oligomeric compound of any one of claims 1-288 or 291, the population of any one of claims 289-290, or the antisense compound of claim 292 or claim 293, or the pharmaceutical composition of any one of claims 294-296 comprises a bicycle ligand having affinity for a transferrin receptor.
318. The oligomeric duplex or oligomeric compound of any one of claims 1-288 or 291, the population of any one of claims 289-290, or the antisense compound of claim 292 or claim 293, or the pharmaceutical composition of any one of claims 294-296 for use in for treating or preventing a disease, disorder or condition associated with a damaged, weakened and / or overworked heart or heart failure.
319. Use of the oligomeric duplex or oligomeric compound of any one of claims 1-288 or 291, the population of any one of claims 289-290, or the antisense compound of claim 292 or claim 293, or the pharmaceutical composition of any one of claims 294-296 for treating or preventing a disease, disorder or condition associated with a damaged, weakened and / or overworked heart or heart failure.
320. Use of the oligomeric duplex or oligomeric compound of any one of claims 1-288 or 291, the population of any one of claims 289-290, or the antisense compound of claim 292 or claim 293, or the pharmaceutical composition of any one of claims 294-296 in the manufacture of a medicament for treating or preventing a disease, disorder or condition associated with a damaged, weakened and / or overworked heart or heart failure.
321. The use of any one of claims 318-320, wherein the disease, disorder or condition associated with a damaged, weakened and / or overworked heart or associated with heart failure is cardiomyopathy, cardiac arrythmia, and / or heart failure.
322. The use of claim 321, wherein the cardiomyopathy is genetic cardiomyopathy.
323. The use of claim 322, wherein the genetic cardiomyopathy is associated with PLN p.Argl4del, Arg9Cys (R9C), or Arg25Cys (R25C) genetic mutations.
324. The use of claim 321, wherein the cardiomyopathy is dilated cardiomyopathy (DCM).
325. The use of claim 324, wherein the DCM is genetic DCM.
326. The use of claim 325, wherein the genetic DCM is associated with TTN, LMNA, RBM20,SCN5A, MYH7, TNNT2, or TPM1 mutations.
327. The use of claim 324, wherein the DCM is arrhythmogenic DCM.
328. The use of claim 321, wherein the heart failure is heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), acute heart failure, or worsening of chronic heart failure.
329. The use of claim 321, wherein the arrhythmia is ventricular tachycardia (vtac) or ventricular fibrillation (vfib).
